Skip to main content
International Journal of Pharmaceutics: X logoLink to International Journal of Pharmaceutics: X
. 2026 May 26;11:100575. doi: 10.1016/j.ijpx.2026.100575

Stabilization strategies and advancements in lyophilization to preserve integrity and efficacy of next-generation biologicals

Ravi Maharjan a, Chang Yell Shin b, Seon-Kwang Lee c, Eun-Sol Ha c, Heejun Park d, Jeong-Soo Kim d, Ki Hyun Kim e, Nam Ah Kim e, Min-Soo Kim c,⁎, Seong Hoon Jeong a,⁎
PMCID: PMC13234487  PMID: 42253757

Abstract

The success of mRNA-lipid nanoparticles (LNPs) vaccines during the COVID-19 pandemic has significantly increased global demand for stable, thermo-resistant biologicals. Lyophilization remains a cornerstone technology for enhancing the stability of these formulations; however, the freezing and drying processes impose major stresses that can compromise the integrity of fragile LNPs. This review systematically explores the molecular mechanisms by which lyoprotectants, including sugars, polyols, amino acids, and polymers, mitigate challenges such as ice-induced denaturation, dehydration-driven aggregation, and interfacial destabilization. This review emphasizes the importance of optimized sucrose-trehalose combinations and effective ice-nucleation control in preserving encapsulation efficiency and maintaining particle integrity. Furthermore, the review discusses advanced process optimization tools, including digital twin modeling and in-line Raman spectroscopy, which enhance lyophilization efficiency by reducing primary drying times by up to 40% while ensuring critical quality attributes are preserved. Additionally, emerging applications utilizing novel excipient combinations are highlighted, showcasing their potential to enable refrigerated storage of viral vectors. With 85% of commercial conjugates relying on lyophilization, recent advancements in continuous freeze-drying technology, such as spin-freeze approaches, have achieved cycle times that are three-fold faster. These developments provide a comprehensive roadmap for overcoming cold chain limitations while addressing the stabilization needs of next-generation biologicals, CRISPR-based systems, and personalized medicines.

Keywords: Lyophilization/freeze-drying, Stabilization, Digital twin modeling, Cold chain delivery, Process optimization, Personalized medicines, Ice nucleation

Graphical abstract

Unlabelled Image

Highlights

  • •

    Sugars like sucrose and trehalose replace water to protect biologicals.

  • •

    AI and digital twins optimize drying and cut development time.

  • •

    Freezing and drying cause stresses like pH shifts and denaturation.

  • •

    Continuous spin-freezing achieves up to threefold faster cycle times.

  • •

    Controlled nucleation improves efficiency with uniform ice crystals.

1. Introduction

Biologicals offer therapeutic advantages over low-molecular-weight drugs and hold strong potential for treating life-threatening diseases (Song et al., 2017). During the COVID-19 pandemic, messenger RNA (mRNA) vaccines were rapidly developed using lipid nanoparticle (LNP) technology (Li et al., 2023). Despite their efficacy and safety, RNA–LNP vaccines are inherently unstable, requiring cold-chain and deep-freeze conditions for transport and storage (Uddin and Roni, 2021). To address this limitation, lyophilization has emerged in biopharmaceutical development as a key strategy for improving drug stability (Herrmann et al., 2024; Shirane et al., 2023). Lyophilization (freeze-drying) consists of three stages: freezing (including annealing), primary drying, and secondary drying, during which water is removed from frozen liquid formulations via sublimation. However, freezing and drying can impose physicochemical stresses that compromise final product stability (Bjelošević et al., 2020). Therefore, stabilization strategies such as optimized lyophilization processes (Karunnanithy et al., 2024; Wang, 2000) and the incorporation of stabilizers, including sugars, polyols, amino acids, polymers, and surfactants, are essential (Thakral et al., 2021; Wang, 2000).

To enhance product stability, various lyophilization strategies have been developed (Bhujel et al., 2025). Both conventional approaches, such as quality by design (QbD) and design of experiments (DoE), and innovative techniques including digital twin technology, are being explored to optimize product and process performance (Goldman et al., 2018; Klepzig et al., 2020; Maharjan and Jeong, 2022; Maharjan et al., 2025; Maharjan et al., 2021). Furthermore, lyophilization parameters must be carefully optimized to improve biologicals stability. Since biologicals are highly sensitive to manufacturing conditions, the entire workflow, from formulation and processing to transport and storage, requires rigorous control (Elsayed et al., 2023). Accordingly, various analytical tools, including real-time monitoring technologies, have been developed to optimize lyophilization process parameters (Alejo et al., 2024). Stability is commonly evaluated by assessing quality attributes such as size and size distribution, surface charge, drug retention, residual moisture, collapse temperature, cake appearance, and reconstitution time (Gatto and Najahi-Missaoui, 2023; Luo et al., 2021).

This review presents a novel contribution to the field of biopharmaceutical formulation by synthesizing existing literature on LNP and protein formulations under lyophilization stress conditions while highlighting critical gaps in our understanding of structure-stability relationships. By integrating insights from various disciplines, including biophysics and materials science, we provide a comprehensive overview that not only summarizes current findings but also proposes a framework for future research directions. Our analysis emphasizes the importance of specific structural features such as lipid composition, particle size, protein folding patterns, and choice of lyoprotectants in influencing the stability of formulations during lyophilization. Furthermore, we advocate for the adoption of advanced analytical techniques to elucidate these relationships, ultimately paving the way for the rational design of more resilient biopharmaceutical products. This work aims to enhance the stability and efficacy of LNPs and protein-based therapies with advanced process optimization tools (digital twins, artificial intelligence/machine learning (AI/ML), inline Process Analytical Technology (PAT)), thereby improving patient accessibility to innovative treatments and ensuring better therapeutic outcomes in clinical applications.

2. Lyophilization and the role of stabilizers

2.1. Lyophilization mechanics

Lyophilization preserves biologicals by removing water via sublimation through three stages: freezing, primary drying, and secondary drying. During freezing, the formation of ice crystals leads to freeze-concentration, where solutes become increasingly concentrated, significantly increasing viscosity and potentially shifting pH which may hinder further ice crystallization (Fonte et al., 2016). While these mechanics are foundational, next-generation modalities like mRNA-LNPs and viral vectors face unique structural threats during this phase. Unlike single-protein therapeutics, these complex assemblies are sensitive to mechanical stress from ice crystals and surface denaturation at the ice-water interface, which can lead to lipid membrane rupture, drug leakage, or capsid dissociation. In the drying stages, dehydration replaces hydration shells with protective glassy matrices. For complex biologicals, maintaining the structure-stability relationship is paramount. For instance, the stability of an LNP is dictated not just by protein folding, but by its lipid composition, particle size, and surface charge. Understanding how these structural features interact with excipients during the phase transition from liquid to solid is essential for the rational design of resilient next-generation products. For efficient drying, the formation of large ice crystals with low surface area might be desirable and can be regulated by controlling the freezing rate and temperature (Butreddy et al., 2021). During the freezing step, biologicals experience multiple stress factors, including low temperature, cold denaturation, concentration effects, ice–water interfaces, change in ionic strength, pH shifts, and phase separation (Butreddy et al., 2021; Kasper and Friess, 2011; Wang, 2000). Most of these stresses result from local compositional changes driven by solute freeze concentration during phase separation. For example, during freezing, ice–water interfaces may form, promoting protein adsorption that can induce denaturation of native structures. As ice forms, solute concentrations increase significantly, potentially compromising the stability of the active pharmaceutical ingredients. Additionally, selective crystallization of buffer species can alter pH and ionic strength (Butreddy et al., 2021; Strambini and Gabellieri, 1996; Wang, 2000). In Fig. 1, the various physical and chemical stressors that occur during the freezing stage of lyophilization are shown, which can lead to the degradation of nanoparticles. The process begins with mechanical stress from ice crystals and surface denaturation at the ice-water interface, both of which threaten the structural integrity of the particles. Additionally, as freezing progresses, the increased concentration of solutes and significant pH fluctuations compromise the electrostatic stability of the solution. These shifts often cause phase separation, leaving the nanoparticles without their necessary protective stabilizers. The cumulative effect of these destabilization factors results in drug leakage and particle aggregation, ultimately causing the failure of the final product. Through this sequence, it highlights how environmental changes during freezing directly impact the stability and efficacy of encapsulated medicines (Trenkenschuh and Friess, 2021).

Fig. 1.

Fig. 1

Destabilization factors and immediate effects during lyophilization freezing stage (Left to right). Mechanical stress from ice and excipient crystals (mannitol, glycine) causes nanoparticle deformation and rupture; fast super-cooling generates small ice crystals with high interfacial areas, inducing surface denaturation; freezing concentrates solutes up to 50×, increasing ionic strength and osmotic pressure; pH shifts up to 3 units due to buffer crystallization or pKa changes compromise electrostatic stability; phase separation splits nanoparticles from stabilizers, causing loss of protection, drug leakage, aggregation, and final product failure (Trenkenschuh and Friess, 2021).

To ensure scientific precision in process design, three fundamental critical temperatures are defined. The glass transition temperature of the bulk formulation (Tg) represents the point where a dry amorphous solid transitions from a rigid glassy state to a mobile rubbery state, a transition that must be avoided during storage to prevent instability. In contrast, the glass transition temperature of the maximally freeze-concentrated solute (Tg') occurs during the freezing stage when the remaining non-ice phase becomes viscous that further crystallization of water is hindered. The collapse temperature (Tc) is the temperature at which the frozen matrix can no longer support its own weight, leading to macro- or micro-collapse of the cake structure. While Tg' and Tc are closely related, Tc is typically several degrees higher than Tg' and serves as the practical upper limit for product temperature during primary drying to ensure cake integrity. The drying stage of lyophilization comprises primary drying, during which ice sublimates, and secondary drying, in which bound water is removed. During primary drying, chamber pressure is reduced to enable ice sublimation, and product temperature (Tp), although not directly controlled, must remain below glass transition temperature (Tg′) to prevent cake collapse. Following this, secondary drying aims to eliminate residual water by increasing the shelf temperature. During this phase, the desorption process occurs, wherein water molecules that are tightly bound to the product matrix are released, leading to further increases in the Tg of the formulation. This rise in Tg allows for drying at higher temperatures without compromising product integrity. However, drying frozen products necessitates harsh conditions, such as low pressure, which can adversely affect the physical and chemical stability of biologicals (Randolph, 1997).

The primary stress during drying is dehydration. Hydrogen bonding is crucial for maintaining the structure and stability of biologicals, providing directional interactions that underpin molecular recognition, protein folding, and overall structure (Hubbard and Haider, 2010; Hung et al., 2021). Fully hydrated proteins in aqueous solutions are surrounded by a monolayer referred to as the hydration shell. Partial removal of this shell during lyophilization can cause protein denaturation. Dehydration may also transfer protons to ionized carboxyl groups, reducing protein charges and promoting hydrophobic interactions that lead to protein aggregation (Wang, 2000).

Hydrogen bonding remains critical for nucleic acid therapeutics. RNA–LNPs are typically prepared using a microfluidic system that mixes an organic phase (ethanol) containing lipids with an aqueous RNA solution (Kim et al., 2023). Aqueous ethanol can influence LNP stability through hydrogen bonding and hydrophobic interactions (Hardianto et al., 2023), suggesting that dehydration may affect RNA–LNP stability. Although lyophilized products may remain stable immediately after lyophilization, they can rapidly lose bioactivity during storage. Stability during storage is affected by factors such as storage temperature, formulation glass transition temperature, pH, moisture content, and excipient type (Butreddy et al., 2021; Wang, 2000). Reported instability mechanisms for freeze-dried biologicals during storage include aggregation, chemical degradation, Maillard reactions, oxidation, deamidation, and hydrolysis (Fonte et al., 2016; Wang, 2000; Wijewickreme and Kitts, 1997). Packaging materials and extractable or leachable compounds from packaging materials can also affect the stability of lyophilized products (Butreddy et al., 2021).

2.2. Role of stabilizers

To maintain the stability of complex biologicals during lyophilization and long-term storage, the inclusion of stabilizers is highly recommended (Degobert and Aydin, 2021). While many excipients are utilized across various platforms, their effectiveness is very specific to modality. While disaccharides like sucrose are effective for protein stabilization through water replacement, their use in LNPs is specifically necessitated by the need to maintain the internal aqueous domains of the lipid assembly. For proteins, sugars primarily substitute for the hydration shell to prevent unfolding. In contrast, the internal organization of an LNP is not fully anhydrous; the core contains approximately 24% (v/v) water where the genetic payload resides. Consequently, stabilizers in LNP formulations must not only provide a vitrified matrix but also directly protect these internal lipid-RNA assemblies through specific hydrogen bonding. Furthermore, the selection of secondary stabilizers reflects differing physical challenges. For instance, amino acids like arginine are frequently added to high-concentration mAbs primarily to reduce viscosity and enhance protein solubility during reconstitution. Conversely, in viral vector and LNPs, ionic excipients are often limited or avoided because they can lower the formulation's glass transition temperature (Tg) or induce salt-induced pH shifts that compromise the electrostatic stability of the particles.

Table 1 summarizes the different excipients (stabilizers) used in lyophilized formulations, including sugars, polyols, amino acids, polymers, and surfactants, along with their representative examples, advantages, limitations, and modality-specific applications. Sugars such as sucrose and trehalose offer high glass transition temperatures and water replacement capabilities but may crystallize at high concentrations, making them ideal for mRNA-LNPs and proteins. Polyols like mannitol provide structural support but have low Tg values, while amino acids enhance solubility and pH buffering yet require combination with other stabilizers. Polymers including PEG and PVP provide steric exclusion and high Tg but may increase viscosity, and surfactants such as polysorbate 80 offer interfacial protection despite potential degradation under stress. This comparative overview guides formulation scientists in selecting appropriate stabilizers based on the specific requirements of their drug products.

Table 1.

Different excipients (Stabilizers) used in the lyophilization process along with their advantages, limitations, and modality-specific applications.

Stabilizer Type Examples Advantages Limitations Modality-specific applications
Sugars Sucrose, Trehalose, Maltose high Tg, water replacement, glassy matrix formation may crystallize at high concentrations LNPs: Critical for maintaining internal aqueous domains. Proteins: Essential for hydration shell replacement
Polyols Mannitol, Sorbitol structural support, bulking agent low Tg, may crystallize Viral Vectors/Proteins: Preferred as bulking agents in combination with sucrose to prevent cake collapse
Amino Acids Arginine, Glycine, Histidine solubility enhancement, pH buffering low Tg when used alone Proteins: Used to manage viscosity in high-concentration mAbs.
Viral Vectors: Utilized to neutralize surface charges
Polymers PEG, PVP, Dextran steric exclusion, high Tg may increase viscosity Viral Vectors/mAbs: Provides a robust protective matrix and prevents surface-induced aggregation
Surfactants Polysorbate 80, Poloxamer 188 interfacial protection, aggregation prevention may degrade under stress All Biologicals: Essential for mitigating stresses at the ice-water interface during freezing and reconstitution

2.2.1. Sugars and polyols

Sugars and polyols, typically sucrose, trehalose, maltose, mannitol, and sorbitol, are widely used to stabilize lyophilized products (Chauhan et al., 2026). Sugar and polyol stabilization mechanisms include water replacement, glassy-state stabilization, matrix densification, and the creation of a water-like environment (Butreddy et al., 2021). One primary mechanism is water replacement, where these stabilizers substitute for water molecules surrounding proteins, thus maintaining essential hydration shells that preserve protein conformation during the drying process. The water replacement helps prevent denaturation and aggregation by forming a glassy matrix that immobilizes proteins, reducing their mobility and susceptibility to environmental stresses. Moreover, the effectiveness of these stabilizers often depends on their concentration in the formulation. A minimum sugar-to-protein weight ratio of 1:1 is typically necessary for stability, with an optimal range of approximately 3:1 to 5:1 (Thakral et al., 2021). However, excessive sugar concentrations can compromise stability during lyophilization and storage. Disaccharides, such as sucrose, are generally more effective than monosaccharides due to their higher glass transition temperatures (Tg), which facilitate better stabilization during the freeze-drying. However, increased steric hindrance may weaken hydrogen bonding with the dried product, highlighting the need to balance Tg with hydrogen-bonding capacity. Consistent with this, raffinose, a trisaccharide with a higher glass transition temperature, is less effective than sucrose, a disaccharide (Davidson and Sun, 2001; Thakral et al., 2021; Wang, 2000).

2.2.2. Amino acids

Amino acids serve as important excipients in lyophilized formulations, contributing to the stabilization of biologicals through various mechanisms. Their primary role involves enhancing solubility and reducing viscosity, which is particularly beneficial for high-concentration protein formulations. Amino acids, including arginine, serine, glycine, histidine, lysine, proline, isoleucine, glutamic acid, and phenylalanine, are used as excipients in biopharmaceutical formulations to enhance solubility, control pH, and improve stability (Arakawa et al., 2007; Forney-Stevens et al., 2016). Amino acid-mediated stabilization may involve hydrogen bonding, preferential interactions, improved solubility with reduced viscosity, modulation of molecular mobility, and buffering or antioxidant effects. Amino acids like arginine and glycine can interact favorably with proteins, promoting solubilization and preventing aggregation during the lyophilization process. Arginine and arginine hydrochloride, which enhance protein solubility and reduce solution viscosity, are the most studied amino acids in lyophilization (Izutsu et al., 2005; Nguyen et al., 2024; Stärtzel, 2018). Additionally, amino acids can stabilize proteins through hydrogen bonding and preferential hydration, which helps maintain their native conformation during drying and storage (Butreddy et al., 2021; Thakral et al., 2021). This stabilization mechanism is crucial because it mitigates the risks of denaturation and aggregation that can occur due to dehydration and concentration effects during lyophilization. Furthermore, the buffering capacity of certain amino acids can help maintain the pH of the formulation, providing an additional layer of stability by preventing pH-induced denaturation. While amino acids are effective stabilizers, their relatively low glass transition temperatures (Tg) compared to sugars can limit their effectiveness when used alone. Therefore, they are often combined with sugars or other stabilizers to enhance overall formulation stability (Karunnanithy et al., 2024). By leveraging these mechanisms, the researchers can optimize the use of amino acids in lyophilized formulations to improve the stability and efficacy of biopharmaceutical products.

2.2.3. Polymers

Polymers play a significant role in the stabilization of lyophilized biologicals by enhancing their physical and chemical stability during the freeze-drying process. Some polymers, including cyclodextrin, dextran, polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), polyvinyl alcohol, carboxymethyl cellulose, and gelatin, are widely used to stabilize biopharmaceutical formulations during lyophilization (Thakral et al., 2021; Wang et al., 2023). For instance, polymers such as PEG and dextran can create a protective matrix around proteins, thereby preventing aggregation and maintaining structural integrity during storage. Their higher glass transition temperatures enable drying at elevated temperatures and may improve the long-term stability of lyophilized products (Bjelošević et al., 2020). The mechanisms by which polymers stabilize biologicals include competitive inhibition, steric exclusion, and preferential exclusion (Butreddy et al., 2021). Competitive inhibition occurs when polymers occupy binding sites on proteins, thereby preventing protein-protein interactions that lead to aggregation. Steric exclusion refers to the physical space that polymers occupy, which can hinder the close proximity of proteins and further reduce aggregation risk. Preferential exclusion involves the polymer preferentially interacting with water, effectively reducing the local concentration of proteins and stabilizing them during drying. Moreover, certain polymers can also enhance the solubility and stability of lyophilized products by forming hydrogen bonds with proteins, which helps maintain their native conformation. This is particularly important for sensitive biologicals that are prone to denaturation. By understanding these mechanisms, the pharmaceutical scientists can effectively utilize polymers in lyophilized formulations to enhance the stability and efficacy of biopharmaceutical products. For instance, dextran, which is approved for parenteral administration, stabilizes monoclonal antibody (mAb) when combined with sucrose, maintaining stability at 40 °C for 14 days (Haeuser et al., 2020).

2.2.4. Surfactants

Surfactants, or surface-active agents, are compounds that reduce the surface tension mainly between two liquids or between a liquid and a solid. They are widely used to preserve the bioactivity of biopharmaceutical products during lyophilization (Alejo et al., 2024; Karunnanithy et al., 2024; Kim et al., 2014; Oude Blenke et al., 2023). During processing, proteins may adsorb at air–liquid, ice–liquid, or ice–air interfaces, leading to aggregation of surface-active proteins (Thakral et al., 2021). Incorporating surfactants into formulations is therefore an effective strategy to stabilize biologicals. In particular, non-ionic surfactants such as polysorbate and poloxamer effectively inhibit aggregation in both liquid and lyophilized products (Kim et al., 2014). Surfactant-mediated stabilization involves preferential binding and surfactant–protein complex formation, which prevents protein–protein interactions (Butreddy et al., 2021; Thakral et al., 2021). Consequently, surfactants improve not only chemical and higher-order structural stability but also physical stability, especially by inhibiting aggregation of nano-drug delivery systems. They play a crucial role in various applications, including detergents, emulsifiers, and foaming agents. Fig. 2 explains four primary mechanisms used to stabilize therapeutic proteins through chemical and physical interventions. One approach involves using sugar-based water replacement, where molecules like sucrose form hydrogen bonds to maintain the protein's structure in the absence of hydration. Another method utilizes cyclodextrins to shield hydrophobic residues, effectively preventing the proteins from clumping together. Stability is also achieved through surfactant interface competition, which displaces proteins from potentially damaging surfaces into a safer bulk solution. Finally, the process of glassy state vitrification immobilizes the protein within a rigid, amorphous matrix to severely limit molecular movement and unfolding. Together, these techniques ensure that delicate biopharmaceutical treatments remain functional and intact during storage or processing (Pardeshi et al., 2023; Serno et al., 2011; Vinciguerra et al., 2022). By reducing the interfacial tension, surfactants facilitate the formation of stable emulsions, making them essential in food, cosmetics, and pharmaceuticals (Thakral et al., 2021).

Fig. 2.

Fig. 2

Molecular bonding & complexation—trehalose/sucrose form hydrogen bond with polar protein residues, which acts as an alternative to water, thereby preventing protein denaturation (left, top) (Vinciguerra et al., 2022); Cyclodextrin hydrophobic shielding—hydrophobic protein residues (Phe, Trp, Tyr) enter hydrophobic cavity of cyclodextrin, shielding them from unwanted interactions and preventing aggregation (left, bottom) (Serno et al., 2011); Physical matrix & interface protection—surfactants adsorb at interfaces, displacing proteins from the surface into the bulk solution, thereby protecting proteins from surface-induced denaturation (right, top) (Thakral et al., 2021); Glassy state vitrification—therapeutic proteins are immobilized within a rigid, amorphous glassy matrix, which restricts molecular mobility and prevents unfolding (right, bottom) (Pardeshi et al., 2023).

2.3. Application of stabilizers

Recent studies have explored novel stabilizers in addition to conventional excipients (Bjelošević et al., 2020; Holm et al., 2021; Tosstorff et al., 2020). For instance, Bodzen et al. investigated the long-term stability of lyophilized lactic acid bacteria using new lyoprotectants composed of whey, micellar casein, and inulin mixed with sucrose (Bodzen et al., 2021). The results show that combining micellar casein, which supports long-term storage stability, with sucrose, which protects during freezing, preserves high bacterial viability. Consequently, increasing emphasis has been placed on developing innovative stabilizers alongside conventional ones to improve biological stability during processing (Fan et al., 2024). Hermann et al. proposed a novel polymer stabilizer, hyperbranched poly(3-(oxiran-2-ylmethoxy)propane-1,2-diol), for preserving mRNA and self-amplifying RNA–LNPs (Herrmann et al., 2024). This non-toxic stabilizer enhances hydration through its unique topology and forms strong interactions with formulations, thereby maintaining biological integrity. Table 2 lists the stabilizers and process conditions reported in the literature for lyophilizing RNA-based therapeutics. It presents overview of various types of stabilizers, providing key characteristics and common applications for each type. The table also includes examples, illustrating their diverse applications across industries. Overall, Table 2 effectively highlights the functional diversity of stabilizers and their significance in various formulations during lyophilization process.

Table 2.

Different stabilizers used and lyophilization process conditions adopted for RNA-based therapeutics.

Contents Lyo-condition RNA type Stabilizer Reference
Sucrose (8.8%), trehalose (2%), and mannitol (0.04%) mixture, increased eutectic point and collapse temperature, thereby enhancing lyophilization efficiency of mRNA-LNPs. Lyophilized product stored at 2–8 °C for 1 month showed no significant changes in encapsulation efficiency or mRNA integrity. In contrast, unfreeze-dried shows a slight decrease. Freezing: 4 h
Primary drying: 2 h
Secondary drying: 2 h
mRNA Glucose, lactose mannitol, sucrose, trehalose (Li et al., 2023)
Lyophilized siRNA-LNPs containing sucrose (high miscibility) demonstrated effective stabilization. Freezing: −40 °C, 3 h
Drying: −30, −20, −10, 0, 10, and 20 °C for 6 h (1 h at each temperature), < 3 Pa
25 °C, > 5 h
siRNA Cyclodextrin, mannitol, sorbitol, sucrose, trehalose (Shirane et al., 2023)
Lyophilized mRNA-LNPs encoding luciferase or hEPO, containing sucrose and using the dilution-lyophilization method, maintained in vivo mRNA transfection at 4 °C for 1 month. Freezing: −40 °C, 1 h
Drying: −30, −20, −10, 0, 10, and 20 °C for 6 h (1 h at each temperature)
30 °C, > 3 h
mRNA Sucrose (Shirane et al., 2023)
Lyophilized mRNA-LNPs containing novel polymer, HPOD (having excellent hydration and biocompatibility). mRNA Hyperbranched poly(3-(oxiran-2- ylmethoxy)propane-1,2-diol, sucrose, trehalose (Herrmann et al., 2024)
Optimal lyophilization conditions established based on buffers/stabilizers screening. Lyophilized products stored at 4 °C for 12 months showed no significant changes in physicochemical properties and in vivo activity. Freezing: −50 °C, 1.6 °C/min, 5 h
Primary drying: −15 °C, 0.5 °C/min, 12 h, 180 mTorr
Secondary drying: 30 °C, 0.5 °C/min, 7 h, 100 mTorr
mRNA Maltose, sucrose (Alejo et al., 2024)
Lyophilized biologicals containing luciferase, wild-type, Delta, or Omicron mRNA, along with stabilizer, stored at 25 °C for 6 months, showed no changes in physicochemical properties or bioactivity. Freezing: −40 °C
Drying: ∼25 °C for 40 h
mRNA Sugar (Ai et al., 2023)
Lyophilized liposomes containing chitosan/PEG 2000 stored at 4 °C for 1 month showed no significant changes in encapsulation efficiency. However, particle size may increase/decrease depending on RNA type/storage duration. Freezing: −80 °C, 1 h
−50 °C, 20 min
Primary drying: −15 °C for 2 h0
 °C for 1 h
Secondary drying: 25 °C, 30 min, 0.1 mbar
Circular RNA and mRNA Sucrose (Altay Benetti et al., 2024)
Lyophilized siRNA-LNPs with sugar showed no signs of cake collapse. 20% sugar preserved efficacy after reconstitution. Freezing: −80 °C siRNA Sucrose, trehalose (Ball et al., 2017)
Lyophilized LNPs with poly(β-amino esters) and DOTAP, stored at 4 °C for 6 months, showed no change in particle size and zeta potential while transfection efficiency significantly decreased within 1 month. Freezing: −80 °C, 2 h
Drying: −80 °C, 12 h, 0.01 mbar
mRNA Sucrose (Cao et al., 2022)
Lyophilized miRNA with mesoporous silica nanoparticles, polyethylenimine, in a core-cone structure and 5% trehalose, preserved efficiency and functionality for 6 months at 30 °C. Freezing: −80 °C, 2 h
Drying: −80 °C, 24 h, 0.01 bar
miRNA Trehalose (Hosseinpour et al., 2021)
Lyophilized mRNA-LNPs encoding firefly luciferase or hemagglutinin with stabilizers showed no changes after 3 months and at 4 °C for 6 months. Freezing: −45 °C, 3 h
Primary drying: −25 °C, 84 h, 20 mTorr
Secondary drying: 30 °C, 5 h, 20 mTorr
mRNA Maltose, sucrose (Muramatsu et al., 2022)
Lyophilized mRNA-LNPs at different concentrations of sucrose. Lyophilized products containing 16% sucrose at 5 °C, 25 °C, and 40 °C for 1 month showed increased particle size and reduced mRNA integrity at higher storage temperature and longer duration. Freezing: −40 °C, 4 h
Primary drying: −40 °C, 45 h, ∼3 Pa
Secondary drying: 10 °C, 66 h, ∼3 Pa
mRNA Sucrose (Suzuki et al., 2022)
Lyophilized saRNAs with nanostructured lipids demonstrated thermal stability at 4 °C for 10 months and at 25 °C for 6 months. Freezing: −50 °C
Primary drying: −30 °C, 50 mTorr
Secondary drying: 25 °C, 50 mTorr
Self-amplifying RNA Sucrose (Voigt et al., 2022)
Lyophilized circRNA-LNPs with modified mannose showed no physical changes at 4 °C for 6 months. Freezing: −45 °C, 2 h
Primary drying: −25 °C, 45 h
Secondary drying: 25 °C, 4 h
Circular RNA Sucrose (Wan et al., 2024)
Lyophilized mRNA-LNPs containing 8.7% sucrose showed no significant change in transfection efficiency when stored at 4 °C for 3 months. Freezing: −30 °C, 3 h
Primary drying: −25 °C, 16–18 h, 5–10 Pa
Secondary drying: 22–27 °C, 5 h, 20 Pa
mRNA Sucrose (Wang et al., 2024)
Lyophilized mRNA-LNPs with 20% sucrose/trehalose showed no change in particle size and in vitro efficacy. mRNA Mannitol, sucrose, trehalose (Zhao et al., 2020)

Abbreviations: miRNA, micro ribonucleic acid; siRNA, small interfering ribonucleic acid; LNP, lipid nanoparticle; saRNA, self-amplifying RNA; circRNA, Circular RNA.

3. Advanced formulation design

3.1. Formulation based on vitrification

Vitrification is the conversion of a solution into a glassy solid during the freezing stage, preventing damaging ice crystal formation and protecting biologicals. In lyophilization, vitrification immobilizes the glassy matrix formed around biologicals, thereby protecting them from environmental stresses such as oxidation, hydrolysis, and aggregation (Merivaara et al., 2021). According to vitrification theory, stability is ensured when biologicals and excipients form an amorphous rather than crystalline solid. The formulation Tg is optimized to maintain a glassy state during storage and transport, and the glassy matrix limits molecular mobility to minimize degradation (Pardeshi et al., 2023). Fig. 3 shows how trehalose functions as a vital protective agent during the cryopreservation and freeze-drying of biological materials. By forming a high-viscous glassy matrix, this sugar prevents the formation of damaging ice crystals and ensures successful post-thaw recovery of cells (Murray et al., 2024). It further acts as lyoprotectants for nanoparticles, shielding them from the mechanical stresses that typically cause permanent aggregation during sublimation. On a molecular level, the water replacement hypothesis suggests that trehalose stabilizes structures by substituting for water molecules through hydrogen bonding. Additionally, its kosmotropic properties disrupt the networks needed for ice growth, while its chemical stability prevents unwanted reactions. According to vitrification theory, stability is ensured when biologicals and excipients form an amorphous rather than crystalline solid. The formulation Tg is optimized to maintain a glassy state during storage and transport, and the glassy matrix limits molecular mobility to minimize degradation (Pardeshi et al., 2023). Crystallization during lyophilization can destabilize biologicals by excluding them from the crystal lattice, which promotes aggregation and loss of activity. Amorphous excipients (trehalose and dextran) inhibit crystallization, promote vitrification (Tambe et al., 2022), and prevent the formation of crystalline domains. Ultimately, these diverse mechanisms work together to maintain the structural integrity and functional viability of sensitive biological samples. These formulation strategies stabilize biologicals during processing.

Fig. 3.

Fig. 3

Schematic representation of the vitrification process and the role of lyoprotectants in the production of stable lyophilized products (A) Vitrification—aqueous suspensions are frozen at a temperature below the freezing point depression, inducing vitrification of the whole sample. Upon optimal dehydration and vitrification of the unfrozen fraction, ice recrystallization is prevented, leading to successful post-thaw recovery (Murray et al., 2024) (B) Role of lyoprotectants—in freeze drying without lyoprotectants, mechanical stress during freezing and drying causes nanoparticle aggregation, leading to unstable products. In contrast, lyoprotectants stabilize the nanoparticles, reducing mechanical stress and preventing aggregation, thereby yielding stable, lyophilized products. The molecular mechanisms of trehalose-based stability is defined with water replacement hypothesis, kosmotropic property, and chemical stability (Pardeshi et al., 2023).

In addition, Fig. 4 illustrates how lyophilization addresses the significant logistical hurdles associated with traditional vaccine distribution. Standard biologicals often require extreme cold storage to prevent degradation, creating a bottleneck for regions lacking expensive deep-freeze infrastructure (Zhi et al., 2023). By utilizing continuous spin-freezing and specialized chemical stabilizers, scientists can transform unstable liquids into thermostable solids. These processed biologicals, such as RNA-LNPs and gene therapies, demonstrate significantly improved shelf lives at much higher temperatures (Liu et al., 2024). Consequently, this technology allows life-saving treatments to remain viable for months or years without the need for specialized sub-zero environments. This transition from frozen liquid to stable solid is essential for ensuring global access to modern medicine. These excipients replace water molecules at biological sites, forming hydrogen bonds that preserve protein structure and prevent aggregation, thereby maintaining bioactivity. Cyclodextrin derivatives, including hydroxypropyl-β-cyclodextrin (HP-β-CD), further enhance protein conformational stability through host–guest interactions. Trehalose analogues with modified hydroxyl groups stabilize the lyophilization by forming hydrogen bonds and creating protective glassy matrix, which prevent the unfolding and aggregation during drying and storage (Pardeshi et al., 2023). Alternatively, synthetic polymer blends such as PVP–PEG copolymers reduce ice crystal formation during primary drying. Trehalose and mannitol improve cryoprotection, whereas silicone dioxide and HP-β-CD enhance adsorption and complexation processes (Zhang et al., 2023b).

Fig. 4.

Fig. 4

Cold chain requirements for biologicals stability and development of thermostable lyophilized products(Zhi et al., 2023) via freeze-drying together with stabilizers and continuous spin-freezing. Post-lyophilization storage stability (temperature maintained at 4 °C) of mRNA-LNP (6 month), AAV8 gene therapy (12-month), and recombinant PRV (24-month) compared to non-lyophilized liquid products (temperature maintained at -60 °C) i.e., mRNA-LNP (6-month), AAV8 gene therapy (12-month), and recombinant PRV (6-month) (Liu et al., 2024). Abbreviations: mRNA, messenger Ribonucleic Acid; AAV8, Adeno-Associated Virus; PRV, Pseudorabies Virus.

To maintain a stable glassy state, the formulation Tg must exceed the storage temperature (Najarian et al., 2024). Accordingly, excipients with high Tg values (trehalose) are commonly used to elevate formulation Tg, while plasticizers and stabilizers (PVP) can modify Tg to ensure vitrification under specific conditions. If the formulation Tg is too low, the system may shift from a glassy to a rubbery state, increasing molecular mobility and accelerating degradation. Amorphous stabilizers, including polymers and carbohydrates, help maintain the glassy state during and after lyophilization (Merivaara et al., 2021). Hydrophilic polymers (PEG and dextran) improve vitrification by forming a stable amorphous phase, while sugars and polyols (sucrose and sorbitol) prevent crystallization during freezing and drying. These stabilizers keep biologicals in an amorphous matrix, reducing the risk of structural changes (Petkov et al., 2024).

Careful control of freezing and drying phases improves vitrification and minimizes mechanical stress on biologicals (Siew, 2018). Optimized drying rates remove residual moisture without collapsing the amorphous structure, resulting in uniform vitrification and improved stability. Since residual moisture lowers formulation Tg and compromises product stability (Siew, 2018), prolonged secondary drying under low pressure is required, and hygroscopic materials such as silica gel may be incorporated to further reduce moisture content. Reducing residual moisture keeps Tg above ambient storage temperatures, thereby maintaining the glassy state. As a result, biologicals remain immobilized within the amorphous phase, preserving stability. Stabilizing biologicals during lyophilization is a complex process that requires precise formulation strategies. Vitrification theory provides a robust framework for understanding and optimizing these strategies (Schiewe and Anderson, 2017). By forming a stable glassy matrix, vitrification immobilizes biologicals and protects them from environmental stress and degradation. Formulation strategies, including cryoprotectant selection, Tg optimization, stabilizer incorporation, and control of freezing/drying rates, are important for maintaining biological integrity (King, 1976). Adherence to these strategies enhances the shelf life, efficacy, and safety of biologicals, addressing the growing demand for stable biopharmaceutical products (Li et al., 2024c).

3.2. Controlled nucleation in lyophilization

Controlled nucleation in lyophilization refers to the deliberate initiation of ice crystal formation during the freezing stage of the process (Kasper and Friess, 2011; Wang et al., 2022b). This technique aims to produce uniform ice crystal sizes, which is critical for enhancing the efficiency of primary drying and maintaining the structural integrity of the product. By controlling the nucleation process, researchers can mitigate the formation of large ice crystals that can damage the product's physical structure and affect its stability (Oddone et al., 2017). Various tools are available in the market to facilitate controlled nucleation, including sonication, mechanical shaking, pressurized freezing, Vacuum Induced Surface Freezing (VISF), and ice fog methods (Regis et al., 2021; Vollrath et al., 2019; Zhang et al., 2014). These methods help to optimize the freezing process by promoting consistent nucleation events, thereby leading to a more homogeneous ice matrix. The impact of controlled nucleation is significant on the lyophilization process. By ensuring uniform ice crystal size, controlled nucleation enhances the sublimation rate during primary drying, which can lead to shorter processing times and improved product quality. Furthermore, this approach can reduce the risk of collapse or shrinkage of the product during drying, contributing to better preservation of the active ingredients. Excipients can affect the thermodynamic properties of the solution, thereby impacting nucleation and crystallization. Additionally, annealing process incorporated to the frozen product at a temperature just below its melting point, can be beneficial. Annealing allows for the rearrangement of ice crystals, promoting their growth and further enhancing the uniformity of the freeze-dried product. Overall, a comprehensive understanding of controlled nucleation and its associated factors is crucial for optimizing lyophilization processes and ensuring the stability of pharmaceutical products.

The controlled crystallization during lyophilization prevents unwanted phase transitions that can cause product degradation. Analytical techniques, including lyophilization microscopy and thermal analysis, enable monitoring and regulation of crystallization (Ward and Matejtschuk, 2021). Novel excipients and additives have enhanced crystallization control. For instance, polymers and surfactants can modify crystallization kinetics and improve the stability of freeze-dried products (Abla and Mehanna, 2022). These additives interact with biological components to form protective layers that inhibit crystallization. Lyophilization parameters such as temperature, pressure, and drying time are optimized to control crystal formation. Lowering temperature and pressure during primary drying reduces ice crystal size, yielding a stable amorphous product (Pardeshi et al., 2023). Adjusting the cooling rate during freezing controls nucleation and ice crystal growth, thereby minimizing crystallization (Emami et al., 2023). The heat/mass transfer primary drying models were tested to predict the product temperature and sublimation time during lyophilization, enabling optimized drying cycles and improved crystallization control (Tchessalov et al., 2023). The transfer of normal operating ranges to a commercial scale freeze-dryer was successful with the developed model and also experimentally verified (Vanbillemont et al., 2025).

Recent years have seen innovative strategies to prevent or control crystallization during lyophilization. For instance, one study optimized buffers, cryoprotectants, and lyophilization parameters to enhance long-term stability and in vivo performance of biologicals (Alejo et al., 2024). Another study developed a lyophilization process for adenovirus-vectored vaccines using a DoE approach to select excipients and improve the cycle, preserving potency and acceptable cake formation (Zhang et al., 2023a). Mannitol provides structural support but requires controlled crystallization to prevent amorphous phase collapse. Thermal annealing (−45 °C → −25 °C) with 2% w/v glycine yields uniform crystalline matrices and reduces reconstitution time by 30% (Rodrigues et al., 2021). Similarly, glycine controls protein crystallization, while trehalose stabilizes the glassy matrix. Furthermore, the incorporation of annealing offers additional benefits over conventional lyophilization, including more uniform crystals, shorter reconstitution time (3 min → 2.1 min), and lower residual moisture (1.2% → 0.8%). Despite advances in crystallization control, lyophilization of biologicals still faces challenges: mannitol crystallization compromises structural integrity (Groël et al., 2023), high residual moisture promotes crystallization and reduces stability, industrial-scale processes make precise condition control difficult (Khan et al., 2024), biological diversity adds complexity (Emami et al., 2023), measuring crystallization often requires resource-intensive techniques, scaling up while maintaining control is challenging, and regulatory compliance must be ensured.

Effective crystallization control relies on analytical methods such as differential scanning calorimetry (DSC), powder X-ray diffraction (PXRD), scanning electron microscopy (SEM), and Fourier transform infrared spectroscopy (FTIR). Controlling crystallization during lyophilization remains a major challenge in pharmaceutical development. Strategies to address this include careful selection of excipients, optimization of process parameters, and advanced formulation techniques. However, ongoing research is needed to address these challenges and improve process efficiency. Future efforts should focus on predictive models for crystallization, novel excipients with enhanced stabilization, and improved analytical techniques for real-time monitoring of crystallization. Integrating these strategies with robust analytics can enhance the stability and quality of biological formulations, ultimately supporting more effective and reliable drug delivery.

3.3. Structural stability

The limited emphasis on structure-stability relationships in lipid nanoparticle (LNP) and protein formulations under lyophilization stress conditions highlights a significant gap in current research and development efforts. Understanding these relationships is crucial for optimizing formulations to enhance their stability and efficacy during lyophilization, which is essential for the successful development of biopharmaceutical products. LNPs, widely used for delivering nucleic acids like mRNA, exhibit unique structural characteristics such as lipid composition, particle size, and surface charge that profoundly influence their stability under lyophilization stress. Variations in lipid composition can affect the fluidity and permeability of the nanoparticle membrane, impacting their response to freezing and drying conditions, while the size and surface characteristics determine interactions with excipients and stabilizers. Similarly, proteins are sensitive to environmental stresses and can undergo denaturation or aggregation during lyophilization, with their structural integrity influenced by folding patterns, hydrophobic interactions, and post-translational modifications. Comprehensive studies that systematically investigate these structure-stability relationships using advanced analytical techniques, such as cryo-electron microscopy and dynamic light scattering, are essential for identifying optimal formulation strategies. By prioritizing this research, the biopharmaceutical industry can develop more robust formulations that withstand the rigors of lyophilization, ultimately improving the shelf life and efficacy of LNPs and protein-based therapies and enhancing patient accessibility to these innovative treatments. A deeper understanding of these relationships will facilitate the rational design of formulations that maintain the integrity of their active components, ensuring better therapeutic outcomes in clinical applications. The cryoprotectants and lyoprotectants mitigate freezing-induced stresses via replacing hydrogen bonds between biomolecules and water, thus protecting the biologicals. Among cryoprotectants, trehalose demonstrates superior protective properties (Tg = −30 °C, 40% aggregation reduction, low glycation risk) compared with sucrose (Tg = −34 °C, 25% aggregation reduction, moderate glycation risk) and HES-sucrose blends (Tg = −28 °C, 40% aggregation reduction, low glycation risk) (Bae et al., 2024). The superior stabilization capacity of trehalose and non-reducing nature, which prevents glycation in heat-sensitive vaccines (Arpagaus, 2023). In hepatitis B surface antigen vaccine, trehalose reduces glycation by 90% compared to sucrose at 25 °C storage and forms a stable amorphous matrix that lowers the energy barrier for water replacement, thereby minimizing interfacial stress during phase transition (Bae et al., 2024). Comparative study shows trehalose outperforms sucrose in preserving structural integrity, reducing particle size and polydispersity by 25% post-lyophilization.

Vitrification at higher temperatures (−32 °C vs. −41 °C for sucrose) enhances scalability for thermosensitive biologicals and stabilizes heat-sensitive mRNA antigens under tropical storage (Bae et al., 2024). At 5% w/v, trehalose maintains nanoparticle dispersity (polydispersity index [PDI] < 0.2) for 6 months at 40 °C. Trehalose forms a glassy state that immobilizes biologicals, preventing conformational changes during freezing and long-term storage. It is used in WHO-prequalified mRNA-LNP COVID-19 vaccines for low-resource settings (Liu et al., 2024). Among cryoprotectants, trehalose demonstrates superior protective properties (Tg = −30 °C, 40% aggregation reduction, low glycation risk) compared with sucrose (Tg = −34 °C, 25% aggregation reduction, low glycation risk) and HES-sucrose (Tg = −28 °C, 40%, low) (Bae et al., 2024). Likewise, beyond existing clinical methods, alpha-galactosylceramide serves as a potent adjuvant for mRNA vaccines targeting intracellular infections and cancer (Meulewaeter et al., 2024).

HES combined with sucrose forms a porous, rigid matrix during freezing, reducing molecular mobility and preventing mAbs aggregation. Sucrose substitutes for water by forming hydrogen bonds with mAbs to maintain native conformation (Li et al., 2024a). Combining trehalose with HES further stabilizes biologicals, preserving tertiary structure via preferential exclusion. These findings establish trehalose-based formulations as widely regarded as effective for next-generation lyophilized biologicals, particularly vaccines requiring thermal stability for global distribution (Li et al., 2024a). The HES-sucrose blend (1:1) reduces IgG1 mAbs aggregation by 40% by forming a rigid porous matrix during freezing, while sucrose preserves hydration shells. This combination shortens primary drying cycles by 15% due to higher Tg values. HES prevents sucrose crystallization at low temperatures, ensuring a uniform lyophilized cake. HES excludes protein from the ice–water interface, while sucrose stabilizes hydration shells, which collectively minimize surface-induced denaturation. HES-sucrose blends enable faster primary drying (Tg = −28 °C vs. -34 °C for sucrose alone), reducing cycle time by 15%. These formulations are now used in commercial adalimumab biosimilars, extending shelf life beyond 36 months (Li et al., 2024a).

Biomimetic materials, such as tardigrade-like CAHS proteins (Cytoplasmic Abundant Heat Soluble), reduce residual moisture to 0.15% (vs. 0.5% in sucrose-based formulations) and maintain enzymatic activity at 50 °C for 18 months (p < 0.01 vs. controls) (Kasianchuk et al., 2023). DNA origami scaffolds with precise 3D nanostructures (20–100 nm) can prevent protein unfolding (Jeon et al., 2025). PVP-PEG copolymers added during freezing improved the removal of ice crystals smaller than 20 μm. HP-β-CD complexes incorporated during primary drying raise the collapse temperature above −35 °C. Silicone dioxide-trehalose combinations in secondary drying reduce residual moisture to 0.5%. Recent innovations include using genetic algorithms and molecular dynamics to design trehalose-poloxamer hybrid stabilizers, achieving a shelf life of 36 months at 25 °C, surpassing the 12-month standard. Cyclodextrin-MOF formulations improve stability by over 55%, while lipid-polymer nanoparticles reduce ice nucleation. Formulations with peptide amphiphiles maintained stability for 9 months at 25 °C, and trehalose‑zinc oxide improves reactive oxygen species scavenging and stabilization. Tardigrade-specific gene incorporation could repair genes and contribute to enhanced thermal stability (Anoud et al., 2024).

3.4. Interfacial stability

Surfactants stabilize biologicals during lyophilization and subsequent storage by protecting their integrity and activity (Imamura et al., 2014). These amphiphilic molecules reduce surface and interfacial tension between phases, such as liquid–solid or liquid–air (Authelin et al., 2020). Their primary mechanism is interfacial stabilization, in which surfactants adsorb at the air–water interface, forming a protective layer around proteins. This layer prevents direct contact with air, reducing denaturation and aggregation. Surfactants also interact with hydrophobic regions of proteins, preserving their native conformation during lyophilization stress (Authelin et al., 2020). Additionally, they mitigate physical stresses, including ice crystal formation and dehydration, by maintaining a stable environment around protein molecules.

Surfactants can reduce ice crystal size, minimizing mechanical stress on proteins (Karunnanithy et al., 2024). Although less common due to potential charge interactions, ionic surfactants can stabilize proteins in specific formulations. Sodium dodecyl sulfate, an anionic surfactant, is occasionally used in lyophilization but is limited by its potential to denature proteins. Recent research focuses on optimizing surfactant type and concentration to maximize stabilization without compromising protein activity. Polysorbate 80 (0.01–0.05%) and Pluronic F68 (0.02–0.1%) shield proteins from ice–water interfaces, while vitamin E TPGS (0.005–0.02% w/v) stabilizes high-concentration mAbs by reducing surface tension at air–water interfaces (Karunnanithy et al., 2024). Poloxamer 188 has been studied as a surfactant alternative to traditional polysorbates such as polysorbate 20 and 80, offering stabilization benefits for biologicals, particularly in lyophilization.(Katz et al., 2022) HP-β-CD has also been compared with traditional polysorbates in mAbs formulations and improves stability, serving as a functional alternative surfactant. Recent studies highlight biosurfactants as sustainable substitutes for synthetic surfactants, with potential applications in stabilizing biologicals (Ceresa et al., 2023).

The effectiveness of surfactants in freeze-dried formulations is evaluated using analytical techniques such as FTIR, DSC, PXRD, Raman spectroscopy, solid-state nuclear magnetic resonance (ssNMR), dynamic light scattering (DLS), size-exclusion chromatography (SEC-HPLC), and dielectric relaxation spectroscopy (Bolje and Gobec, 2021). These analytical techniques are essential for developing and optimizing freeze-dried formulations, ensuring that surfactants maintain protein integrity and prevent degradation during drying. Despite advances in surfactant use for lyophilization, several challenges still remain-not all molecules are stable as freeze-dried solids, and some, such as cephalosporins, are less stable in amorphous form than crystalline one. Surfactants, together with buffers and cryoprotectants, preserve drug stability and lyophilization suitability. However, surfactants and other volatile compounds can be removed under high vacuum, potentially altering pH and critical quality attributes. The process is complex, requiring precise control of multiple parameters, and surfactants add complexity that must be carefully managed to maintain product quality. Lyophilization is an energy-intensive process, and adding surfactants can further increase process demands.

Studies on surfactant interactions have improved biological stability (Brosig et al., 2023). Current efforts focus on optimizing processes to use surfactants more effectively, including developing efficient lyophilization cycles (Sharma et al., 2021). As the industry shifts toward sustainability, environmentally friendly surfactants and processes are gaining importance. The increasing regulatory approvals for lyophilized formulations indicate growing acceptance of advanced surfactant systems. Surfactants protect the biologicals by mitigating interfacial stresses during freezing and reconstitution phases. Recent advancements in surfactant formulations, including Poloxamer 188, HP-β-CD, PNIPAM-PEG block copolymers, and biosurfactants, reflect a growing interest in more effective and sustainable stabilization strategies (Jun et al., 2024). Advanced analytical techniques have enhanced the understanding of surfactant behavior in freeze-dried formulations. While challenges remain, ongoing research and development continue to optimize surfactant formulations by addressing current limitations and expanding their applications across various biologic formulations (Brosig et al., 2023). Continued innovation in lyophilization is expected to further improve the stability and efficacy of biologic drugs.

3.5. Effect of buffers and ionic excipients

Buffers are included in freeze-dried formulations to maintain a stable pH environment for biologicals, as the choice of buffers significantly affects stability and solubility (Pardeshi et al., 2023). Fig. 5 shows the optimization of RNA-LNPs by evaluating the effects of pH levels (3, 4, and 5) and NaCl concentrations (0 mg/mL, 30 mg/mL, 150 mg/mL, and 750 mg/mL) on encapsulation efficiency, particle size, and uniformity. The optimal condition for creating superior, homogeneous particles is identified at pH 3 with 0 mg/mL NaCl, yielding a high encapsulation rate (∼45–50%), a uniform PDI (∼0.10), and a compact size of ∼115 nm. Conversely, high salt concentrations are shown to inhibit encapsulation, increase particle size (up to ∼140 nm), and produce non-uniform particle distributions across all pH gradients. Finally, the figure highlights that a malic acid buffer facilitates the strong lipid-RNA interactions necessary for maintaining LNP integrity during lyophilization and rehydration. For mAbs, histidine-free systems using 5% w/v trehalose maintain pH within ±0.3 units, preventing salt-induced pH shifts during freezing (Noverraz et al., 2023), while 50 mM arginine HCl stabilizes adenoviral vectors by neutralizing surface charges. Commonly used buffers in lyophilization include phosphate, citrate, and histidine buffers, which maintain the desired pH to prevent protein denaturation and aggregation. These buffers provide a stable environment for biologicals during reconstitution and storage and influence the glass transition temperature and crystallization behavior of the formulation (Bjelošević et al., 2020). Ionic excipients further stabilize biologicals by a) interacting with proteins to prevent aggregation and denaturation, b) influencing the solution ionic strength to affect protein solubility and stability, and c) modulating freezing behavior, which affects final product quality (Wang et al., 2022b).

Fig. 5.

Fig. 5

Systematic evaluation of pH (3, 4, and 5) and ionic strength (0 mg/mL, 30 mg/mL, 150 mg/mL, and 750 mg/mL) on the physicochemical characteristics and encapsulation efficiency of mRNA-lipid nanoparticles (LNPs). Abbreviations: RNA, Ribonucleic Acid; LNP, Lipid Nanoparticle.

The buffer system is critical for developing stable freeze-dried biologicals. Recent studies focus on optimizing buffer selection to enhance biological stability. Phosphate buffers are widely used owing to their effective pH range and broad compatibility with biological molecules; however, they can undergo pH shifts during freezing, requiring careful formulation. Citrate buffers are preferred for slightly acidic formulations, offering good buffering capacity between pH 3 and 6 and helping prevent protein aggregation. Histidine buffers are increasingly preferred owing to their ability to maintain protein structural integrity and minimize aggregation, with optimal effectiveness between pH 5 and 7, which is ideal for many biologicals (Wang et al., 2007). Recent research has also explored advanced systems to further enhance stability and compatibility. For example, amino acid buffers such as arginine stabilize proteins and reduce viscosity in high-concentration formulations (Patil et al., 2025).

Ionic excipients help maintain the stability of biologicals through strategies including a) careful adjustment of ionic strength to prevent protein aggregation while maintaining solubility, which requires a delicate balance, as high salt concentrations can increase ionic strength and potentially compromise protein stability; b) combining ionic excipients to achieve synergistic stabilizing effects. For example, using different salts or multifunctional excipients that act as both buffers and stabilizers can enhance overall formulation stability; c) developing novel ionic excipients, including cyclodextrin-based compounds, which stabilize proteins by encapsulating hydrophobic regions and preventing aggregation (Patil et al., 2025).

To effectively optimize biologicals, analytical methods such as FTIR, PXRD, DSC, ssNMR, DLS, and nanoparticle tracking analysis are used to characterize buffer systems and ionic excipients in freeze-dried formulations. These techniques reveal interactions between buffers, ionic excipients, and biologicals, guiding formulation for enhanced stability. Residual moisture (< 1% w/w) and aggregation (< 3% high molecular weight) are monitored via Karl Fischer titration and SEC-HPLC, respectively (ICH Q6B), with reconstitution time (< 2 min) ensuring clinical usability. Modern stabilization strategies integrate material science, process engineering, and computational modeling. As biologicals become increasingly complex, including CRISPR systems and viral vectors, lyophilized formulations remain essential for ensuring global vaccine accessibility. Spray-freeze-drying enables ultrafast freezing (< 100 ms), preserving 98% of hemagglutinin activity in influenza vaccines compared to 85% using tray lyophilization (Gomez and Vehring, 2022; Li et al., 2024b). Neural networks are employed to optimize excipient systems—including trehalose, HES, and Pluronic F68—for interleukin-2 stabilization, which reduces development cycles by 50% (Bharmoria et al., 2024; Ilić-Stojanović et al., 2024; Kumar et al., 2024; Sivasankaran et al., 2024).

Despite advances in formulation strategies for lyophilization, several challenges remain in utilizing buffers and ionic excipients. Key issues include maintaining stable pH during freezing and drying, leading to the development of buffer systems that resist pH shifts; unwanted interactions between buffers and proteins that can destabilize biologicals, prompting innovations in advanced buffers; and the potential for certain ionic excipients to hinder crystallization, affecting the physical stability of the final product. Ongoing research aims to make excipients that preserve an amorphous state during lyophilization, which is crucial for maintaining the functional properties of sensitive biologicals. The use of novel excipients in biopharmaceutical formulations often encounters significant regulatory challenges. These challenges arise from the need for thorough evaluation of the safety and efficacy of new excipients, which can complicate the approval process. However, regulatory pathways like the 505(b)(2) in the United States allow scientists to leverage existing safety data from previously approved products, thereby streamlining the review process and encouraging innovation in formulation strategies. By utilizing the 505(b)(2) pathway, the research scientists can expedite the development of biopharmaceuticals that employ advanced excipients designed to enhance stability and performance, ultimately improving patient outcomes.

The future of formulation strategies for stabilizing biologicals is promising, with several key areas of focus: a) continued development of novel buffer systems that enhance stability and compatibility across a wide range of biologicals; b) development of multifunctional excipients that provide pH buffering, stabilization, and cryoprotection; c) advancements in computational modeling to predict buffer-protein interactions and optimize formulations; d) as personalized medicine advances, focus on developing tailored buffer systems for specific biologic formulations increases, and e) growing emphasis on developing environmentally friendly buffer systems and excipients, aligning with the broader trend toward sustainability in pharmaceutical manufacturing. Careful selection and optimization of buffer systems and ionic excipients can significantly enhance the stability and efficacy of freeze-dried biologicals. Advances in analytical techniques, novel excipients, and predictive modeling are enabling more robust and effective formulation strategies, ultimately improving biologic product stability, efficacy, and shelf life, thereby benefiting patients and pharmaceutical industry.

3.6. Artificial intelligence-based design

3.6.1. Mechanistic and first-principles frameworks

The Michael J. Pikal's foundational work on non-steady-state heat and mass transfer modeling established the physical basis for predicting product temperature, including the Excel-based mechanistic model for secondary drying, which enabled rational prediction of residual moisture evolution without specialized software (Pikal et al., 1984; Sahni and Pikal, 2017). These mechanistic frameworks, such as the diffuse gray surface model used to incorporate radiation exchange between chamber walls and vials, serve as the essential physical “ground truth” for modern Digital Twin systems, where they are synchronized with real-time inline PAT to enable autonomous biomanufacturing (Srisuma et al., 2024a). Complementing these foundational models, the Politecnico di Torino group (Fissore, Pisano, Barresi), whose simplified mechanistic frameworks for in-line process monitoring, real-time optimization, and design-space construction have significantly improved the robustness of conventional batch lyophilization (Fissore et al., 2010). One of the tools, LyoPRONTO is open-source and freely available for lyophilization process optimization (Shivkumar et al., 2019). Furthermore, Srisuma et al. developed a Luenberger observer that combines temperature measurements with mechanistic understanding of heat transfer and desorption kinetics to estimate bound water concentration without requiring direct concentration measurements (Srisuma et al., 2024b).

3.6.2. AI and machine learning in predictive stabilization

Specific studies have demonstrated that digital high-throughput screening (HTS) combined with AI/ML can significantly shorten development timelines (Maharjan et al., 2023a; Maharjan et al., 2024a). For instance, research has shown that AI-driven automated lyophilization can compress candidate screening timelines from a standard 6–8 weeks window to approximately 72 h while handling over 1200 candidates (Maharjan et al., 2024b; Maharjan et al., 2023b). Furthermore, predictive models using 3D graph-based analysis have generated candidate stabilizers with stability prediction accuracies (RMSE) as low as 0.17 (Danishuddin et al., 2023). Similarly, a model trained on 28,000 protein sequences identified 9-mer peptides that reduced mAb aggregation by 63% (Kombo et al., 2024), with synchrotron circular dichroism confirming α-helix stabilization. Federated learning across eight pharmaceutical companies reduced HTS costs by 41% (Heyndrickx et al., 2024), and quantum ML enabled the design of novel stabilizers and patent applications (Qiu et al., 2024). Recent advances employ HTS workflows and generative adversarial networks to design stabilizers with multifunctional properties. Similarly, the computational and software tools were implemented to assist the lyophilization primary drying process development and scale-up based on the model which help predict the product temperature and drying times correctly (Bogner et al., 2021). Blockchain-based data sharing, implemented by the EU LyophAI project, enabled screening of 140 million formulations. Fourier-Domain Low-Coherence Interferometry quantifies cake porosity in the 10–500 μm range (Gomes and Salgueiro, 2022), while cryogenic electron microscopy resolves protein clustering at 2.8 Å during primary drying. The virtual digital twinning within the Pharma 4.0 initiative achieves a 94% correlation between simulated and actual drying curves; primary drying time and collapse temperature can be aligned within ±3.5% (R2 = 0.94).

3.6.3. Integrated PAT for autonomous manufacturing

The integration of real-time PAT with modeling has shown measurable gains in process efficiency in specific case studies. Research utilizing digital twin modeling in conjunction with in-line Raman spectroscopy has reported primary drying time reductions of up to 40% while successfully preserving critical quality attributes. Additionally, robotic workstations like the Hamilton MICROLAB® NGS system have achieved high-throughput processing of up to 5000 formulations per day with a glass transition prediction accuracy of 0.92, though this remains case-specific performance metrics rather than universal process capabilities (Bajrovic et al., 2020). These models optimize process parameters to achieve desired product quality while minimizing crystallization risk. The Hertz–Knudsen formula is used to describe the primary drying phase and the mass balance during secondary drying, as represented in Eqs. (1), (2) (Klepzig et al., 2020):

∂mw∂t=ρw,g.ug.Avial=ρw,g.∆pηw.K.Avial (1)
∂wbw∂t=−kbw.wbw−wbw,eq (2)

where, mw represents the total mass of water, mw,g is the mass of water in the vapor phase, ρw,g denotes water vapor density, ug indicates vapor velocity, Avial is the vial cross-sectional area, Δp represents pressure difference, ηw denotes dynamic viscosity of water vapor, wbw denotes the mass fraction of bound water in the solid product, kbw is the desorption rate constant, and wbw,eq represents the mass fraction of bound water at equilibrium.

k=exp−EAR.Tx (3)

The algebraic partial differential equations are solved using Aspen Custom Modeller™, enabling total process simulations that link lyophilization with other unit operations. Primary drying time prediction and collapse temperature alignment can be achieved within ±3.5% and R2 = 0.94. Robotic workstations such as Echo 655 T (Beckman) can dispense 2500 formulations per day, while the Hamilton Micro system integrates DLS, CD, and FTIR for real-time analysis (Müller et al., 2024).

4. Optimization of processes and quality parameters

The lyophilization process generally includes freezing, primary drying, and secondary drying, which may include an additional annealing step (Kasper and Friess, 2011; Mehanna and Abla, 2022; Thakral et al., 2021). To develop stable biologicals, this process enhances their structural and functional integrity. Fig. 6 compares standard annealing methods with controlled nucleation during the freeze-drying process. When nucleation is not regulated, high supercooling occurs, resulting in small ice crystals that create high resistance to vapor movement and slow down primary drying. Conversely, managing the freezing point leads to larger pores and reduced vapor resistance, which significantly improves drying efficiency and shortens production times. This optimization is a critical quality attribute, though it presents a trade-off where larger crystals may increase the final residual water content. Ultimately, Fig. 6 illustrates how temperature control during freezing dictates the structural integrity and processing speed of lyophilized products (Thakral et al., 2021) (Mehanna and Abla, 2022) Lyophilized products are manufactured under optimized conditions, using various analytical techniques to monitor the process (Alejo et al., 2024). Table 3 summarizes the manufacturing environment, freezing stage, drying stage, storage, transportation, and stability aspects, where key parameters and optimization strategies are enlisted. The testing quality attributes are also included which are helpful in confirming the success of lyophilization process. Moreover, the biologicals and some pharmaceuticals are inherently susceptible to degradation (Kim et al., 2025; Maharjan et al., 2022). A comprehensive management is required throughout the entire manufacturing workflow, from the preparation of liquid formulations to the storage and transportation of final drug products (Ammann, 2011; Elsayed et al., 2023).

Fig. 6.

Fig. 6

Impact of controlled nucleation on quality and productivity of the lyophilization process: maximum allowable water content needs to be determined to optimize the process; smaller pores and reduced water vapor transfer resistance shortens primary drying time while larger specific surface area decreases secondary drying efficiency, potentially increasing residual water content. Large supercooling results in slow sublimation and longer processing times (Mehanna and Abla, 2022; Thakral et al., 2021).

Table 3.

Consideration of manufacturing environment, freezing stage, drying stage, storage, transportation, and stability aspects to determine key parameters and process optimization strategies along with testing quality attributes for a successful lyophilization.

Aspect Key Parameters Optimization Strategies Quality Attributes
Manufacturing Environment - Temperature
- Humidity
- Contamination Control
- Maintain low temperatures to prevent degradation
- Implement stringent cleaning protocols
- Use single-use reagents to minimize contamination
- RNase activity levels
- pH stability
- Particle integrity
Freezing Stage Optimization - Freezing rate
- Annealing temperature
- Final freezing temperature
- Control supercooling to minimize ice crystal size
- Optimize annealing duration and temperature
- Utilize controlled nucleation techniques
- Ice crystal size distribution
- Product temperature during freezing
- Phase separation observations
Drying Stage Optimization - Shelf temperature
- Chamber pressure
- Drying duration
- Adjust shelf temperature and pressure to optimize drying
- Implement dynamic design space analysis
- Monitor product temperature to prevent collapse
- Residual moisture content
- Collapse temperature
- Reconstitution time
Storage and Transportation - Storage temperature
- Packaging integrity
- Transport conditions
- Store under vacuum or refrigeration
- Use appropriate packaging materials
- Monitor transport conditions closely
- Stability during storage
- Encapsulation efficiency
- Physical appearance of the product
Stability Quality Parameters - Particle size and distribution
- Surface charge (Zeta potential)
- Encapsulation efficiency
- Regular monitoring of physicochemical properties
- Optimize formulation components
- Conduct stability studies under various conditions
- Aggregation levels
- Degradation products
- Thermal stability assessments

4.1. Manufacturing environment

mRNA is inherently unstable and is rapidly hydrolyzed both in vivo and outside the human environment. Factors such as temperature, pH, the presence of metallic ions (usually divalent or higher), buffer type, lipid impurities, and RNases can affect mRNA stability (Kafle et al., 2024; Van Pottelberge et al., 2025). Environmental conditions, including residual RNase contamination in manufacturing equipment, improper handling, or suboptimal cleaning protocols, further increase the risk of mRNA degradation. RNase, stabilized by disulfide bonds, degrades poly-ribonucleotides and reduces the half-life of RNA therapeutics (Klink et al., 2000). RNase poses a major risk in RNA-LNP manufacturing, as it may resist common handling procedures such as ethanol washing and steam sterilization. Capillary gel electrophoresis and the RNaseAlert™ Lab Test Kit are two methods for detecting RNase during large-scale manufacturing of biologicals. Case studies in large-scale production show that even trace RNase activity in grade C environments or multi-use DEPC water aliquots can compromise RNA integrity, necessitating rigorous environmental monitoring and single-use reagent strategies (Van Pottelberge et al., 2025).

4.2. Freezing stage optimization

The performance of the subsequent drying stages is largely affected by the morphology of the ice crystals formed during freezing. The degree of supercooling, difference between equilibrium freezing point and the temperature at which ice nucleation actually begins, is the primary driver of this morphology (Wang et al., 2022a). Higher supercooling leads to the formation of numerous, small ice crystals, which create a high surface area interface but also result in high resistance to vapor transfer, thereby slowing down the primary drying rate (Chang et al., 1996; Trenkenschuh and Friess, 2021). To optimize process efficiency, strategies such as controlled nucleation or annealing are usually utilized to reduce supercooling (Lim et al., 2018; Lin et al., 2023). Reduced supercooling promotes the growth of larger ice crystals, which, upon sublimation, leave behind larger pores in the dried matrix. These larger pores offer significantly lower vapor transfer resistance, allowing rapid escape of water molecules and hence faster primary drying. While larger crystals improve processing speed, formulation scientists must balance this against a potential increase in final residual moisture content due to the reduced specific surface area available for desorption during secondary drying. During freezing, crystallization of ice and excipients can cause mechanical damage to formulation systems, including liposomes (Kristiansen, 1992). Furthermore, ice crystal formation within the aqueous core may occur, potentially affecting stability (De Leo et al., 2022; Trenkenschuh and Friess, 2021).

Key process parameters affecting lyophilized product quality during freezing and annealing include freezing temperature, rate, and time, alongside annealing temperature and time (Degobert and Aydin, 2021). To establish optimal lyophilization conditions, the thermal properties of the biopharmaceutical formulation must be characterized. As water freezes, cryo-concentration occurs, leading to eutectic mixture formation as solutes crystallize. The eutectic temperature is the point at which all water in a eutectic mixture freezes into ice (Kasper and Friess, 2011). However, in amorphous materials, increasing viscosity during freezing can allow the system to remain unfrozen even below the eutectic temperature. This process, known as vitrification, occurs at the glass transition temperature, where no further freezing occurs (Duddu and Dal Monte, 1997; Kasper and Friess, 2011). The collapse temperature is the point at which the frozen product structure cannot be maintained, leading to cake collapse. The collapse temperature is typically higher than the glass transition temperature (Horn and Friess, 2018). Key thermal parameters, including eutectic temperature, glass transition temperature, and collapse temperature, can be measured using modulated differential scanning calorimetry and freeze-drying microscopy.

4.3. Drying stage optimization

After freezing, the drying process follows, comprising primary drying (ice sublimation) and secondary drying (desorption of bound water) (Oddone et al., 2017). In the manufacturing of lyophilized products, primary drying is the most time- and energy-intensive stage and is critical for process efficiency and product quality. During primary drying, frozen samples are exposed to harsh conditions such as low pressure, requiring optimization of process parameters, including shelf temperature, heating rate, drying duration, and chamber pressure, to preserve biological stability (Alejo et al., 2024; Bjelošević et al., 2020), ensuring the product temperature remains below the collapse temperature. However, since the product temperature cannot be directly controlled, it is managed by adjusting the shelf temperature and chamber pressure (Jameel et al., 2021). The target product temperature is typically set a few degrees below the critical temperature to ensure efficient drying while maintaining product quality. Recent advances include microwave-assisted lyophilization, which provides uniform heating throughout the product matrix, potentially reducing primary drying times by 30–50% compared to conventional methods (Kalinke et al., 2025).

After primary drying, secondary drying is performed to remove residual moisture from the cake by increasing the shelf temperature (Searles et al., 2017). As secondary drying is an isothermal desorption process conducted at relatively high temperature, process parameters such as shelf temperature, heating rate, drying time, and chamber pressure must be carefully optimized to maintain biopharmaceutical product stability (Howard et al., 2012; Schneid et al., 2011). Determining the drying endpoint is closely related to residual moisture content, which affects the stability of biologicals, including RNA, antibodies, and proteins (AboulFotouh et al., 2024; Breen et al., 2001; Butreddy et al., 2021; Chang et al., 2005). Additionally, the endpoint determination influences process efficiency, making it crucial for optimization. The drying endpoint can be determined using mathematical modeling, including pressure rise technology, and process analytical technologies such as product and shelf temperature measurements, sampling thief, weight measurement, comparative pressure measurement using Pirani and capacitance manometer gauges, NIR and Raman spectroscopy, tunable diode laser absorption spectroscopy, dew point measurements, hyperspectral imaging, thermography, and mass spectrometry (Ahammad and Narayanasamy, 2024; Brouckaert et al., 2018; De Beer et al., 2009; Juckers et al., 2022; Lietta et al., 2019; Patel et al., 2010; Roth et al., 2001; Schneid and Gieseler, 2008; Tang et al., 2006). Establishing a primary drying design space provides a systematic strategy for optimization (Assegehegn et al., 2020). The primary drying design space is typically defined by expressing the ice sublimation rate as a function of chamber pressure and temperature (Kawasaki et al., 2019). Recently, a more advanced strategy, known as the dynamic design space, can optimize process parameters, including chamber pressure and temperature, through uncertainty analysis (Mortier et al., 2016; Vanbillemont et al., 2020).

4.4. Storage and transportation

During storage and transport, it is important to maintain the stability of lyophilized biopharmaceutical products (Ammann, 2011; Elsayed et al., 2023; Maharjan et al., 2024c). A previous study evaluated the stability of freeze-dried CP30A (Eucampyvirinae Fletchervirus) phage using tryptone as a stabilizer during international shipping (Liang et al., 2020). Lyophilized products stored under vacuum refrigeration conditions were more stable than those maintained at ambient conditions, confirming the temperature sensitivity of freeze-dried products. Vial and closure characteristics, including material, size, fill volume, geometry, and stopper material, can affect the process and product stability (Cheng et al., 2025). Furthermore, interfacial stress from shaking during manufacturing, storage, and administration can compromise biological stability (Ruppl et al., 2024).

4.5. Quality parameters for stability

As interest in developing biologicals grows, it becomes very important to ensure the colloidal system stability (Luo et al., 2021). The stability of a colloidal system is influenced by particle and formulation surface chemistry (buffer type, ionic strength, and pH) alongside manufacturing factors such as ice nucleation (Trenkenschuh and Friess, 2021). Thus, it is crucial to analyze and monitor the physicochemical stability of biologicals during lyophilization and storage/transportation. Analytical methods can assess colloidal properties, including particle size and distribution, PDI, surface charge, particle morphology, and drug retention (Gatto and Najahi-Missaoui, 2023). Particle size affects thermodynamic state, influencing stability and drug release, which ultimately affects therapeutic efficacy (Butreddy et al., 2021; Pal et al., 2011). Particle size is typically measured using DLS, also referred to as photon correlation spectroscopy, which analyzes time-dependent fluctuations in scattered light caused by Brownian motion. In addition, DLS can measure particle size distribution and assess uniformity using the dimensionless PDI (Gatto and Najahi-Missaoui, 2023).

The surface charge of a colloidal system, expressed as Zeta potential, indicates the electrical state of the charged interface (Pochapski et al., 2021). A higher absolute Zeta potential indicates stronger electrostatic repulsion between particles, which prevents aggregation and enhances colloidal stability. Zeta potential also determines the tendency of nanoparticles to bind to target cell membranes (Gatto and Najahi-Missaoui, 2023) and is typically measured by placing the solution in a chamber with two electrodes, applying opposite charge to each electrode, and using DLS to correlate particle velocity with charge (Sikora et al., 2016).

Furthermore, particle morphology affects cellular absorption, biodistribution, and surface-binding behavior (Chithrani et al., 2006; Öztürk et al., 2024). Nanoparticle shape is typically examined using scanning and transmission electron microscopy for detailed structural characterization (Gatto and Najahi-Missaoui, 2023). Encapsulation efficiency is assessed in biologicals after lyophilization (Howard et al., 2012). During the process, physical instabilities such as aggregation or collapse can cause drug leakage from particles. The encapsulation efficiency is determined using HPLC (Gatto and Najahi-Missaoui, 2023). For RNA therapeutics, encapsulated nucleic acid concentration can be assessed using Taylor Dispersion Analysis (TDA) (Jiang et al., 2026).

5. Future perspectives

Recently, cell and gene therapy (CGT) and antibody-drug conjugates (ADC) have garnered significant attention in the biopharmaceutical industry due to their potential to treat challenging diseases like certain cancers and genetic disorders (Rafiq et al., 2017). However, their development faces inherent instability issues that can compromise efficacy and shelf life. To address these challenges, researchers are exploring various strategies to enhance stability, such as optimizing formulation components with stabilizers like sugars and amino acids, employing advanced techniques like lyophilization to create stable solid forms, and integrating novel excipients and nanotechnology. This focus on improving the stability of CGT and ADC formulations is crucial for unlocking their full therapeutic potential and ensuring broader patient access to these innovative treatments.

5.1. Adeno-Associated Viruses (AAVs)

Preserving capsid integrity recombinant AAVs is the leading platform for gene delivery but is inherently unstable, often requiring storage below −65 °C. The primary lyophilization obstacle for AAVs is capsid stability; the viral protein shell must withstand the mechanical stresses of freezing and the dehydration of drying without losing the encapsulated genetic payload. During the manufacturing of recombinant AAV-containing drug products, the recombinant AAV may undergo freezing and thawing when the drug substance is frozen and subsequently thawed before filling. For patient administration, frozen drug products must be thawed before use. Previous studies investigated lyophilization to develop a more stable recombinant AAV formulation that can be stored at 2–8 °C (Zhi et al., 2023). The study evaluates excipients, including buffers, lyoprotectants, salts, bulking agents, and surfactants, to produce a stable lyophilized product. The study indicates that a balanced ratio of sucrose to mannitol is critical; mannitol acts as an effective bulking agent, while sucrose provides the necessary thermodynamic stabilization to prevent capsid dissociation (Zhi et al., 2023). Furthermore, non-ionic surfactants are often required to mitigate interfacial stresses during the freezing and reconstitution phases (Merivaara et al., 2021).

5.2. Antibody-drug conjugates (ADCs)

Linker and conjugate stability of ADCs present a dual stability challenge: structural integrity of mAbs and chemical stability of the linker that connects the cytotoxic agent (Fu et al., 2022). Lyophilization is the preferred process for most FDA-approved ADCs to prevent hydrolytic cleavage of these linkers during storage (Wen et al., 2025). To ensure success, formulation scientists must utilize disaccharides with high glass transition temperatures (Tg) to immobilize the conjugate in a rigid matrix (Wang, 2000). The polymers such as sulfobutylether β-cyclodextrin sodium salt, a class of cyclodextrin, serve as solubility enhancers and stabilizers for ADCs (Wen et al., 2025). A specific hurdle for ADCs is the avoidance of ionic excipients; while useful for some proteins, they can lower the formulation Tg and induce destabilization of the drug-linker complex. Emerging analytical tools, such as solid-state hydrogen‑deuterium exchange mass spectrometry, are now being used to evaluate these complex protein-matrix interactions (Cho et al., 2021).

5.3. Continuous and autonomous manufacturing

Beyond modality-specific stabilization, the industry is moving toward continuous lyophilization techniques like spin-freezing, which can reduce cycle times three-fold. These advancements, integrated with AI-driven digital twins and real-time PAT, represent the future of biopharmaceutical manufacturing, enabling the rapid development of stable, “cold-chain-free” biologicals (Adali et al., 2020; Capozzi et al., 2019; Leys et al., 2020; Pisano et al., 2019). A previous study proposes a novel continuous lyophilization, describing its operating principles and equipment (Capozzi et al., 2019). In the study, continuous lyophilization of mannitol and sucrose solutions was conducted using a freeze-dryer composed of modular unit operations for freezing, primary drying, and secondary drying. Vials are suspended on a track and passed through chambers with different pressures and temperatures, separated by load-lock systems to enable continuous flow of vials. This strategy improves heat transfer uniformity and reduces primary drying duration by 2–4 times. SEM analysis revealed enhanced homogeneity between vials and within individual vials (Capozzi et al., 2019). Another continuous manufacturing approach is spin-lyophilization (Schaal et al., 2025). In this process, vials are first spun along their vertical axis while the solution is frozen using cold gas, creating a uniform coating along the inner walls. This increases the sublimation surface area and reduces ice thickness for primary drying. The rotationally frozen vials are subsequently transferred through a load-lock system, vacuum-treated, and transferred to a primary drying chamber equipped with multiple infrared heaters in series. This innovative technology significantly reduces the primary drying time by creating a thin ice layer and ensures uniform processing conditions for all vials compared to conventional batch methods. In addition, in-line monitoring can be employed to assess the quality of each vial (Leys et al., 2020). Previous studies report various strategies for continuous manufacturing (Pisano et al., 2019).

As the biopharmaceutical landscape evolves, regulatory considerations surrounding the implementation of novel excipients and PAT will play a critical role in shaping future developments. The FDA's draft guidance on AL/ML emphasizes the importance of traceability in the validation of these technologies. While standardization of AI/ML processes can provide consistency, the ability to trace the decision-making processes of AI systems is crucial for regulatory compliance. This focus on traceability ensures that PAT can be effectively integrated into the manufacturing process, supporting the development of robust and safe biopharmaceutical products. Moving forward, it will be essential for researchers and developers to stay informed about regulatory expectations and to engage proactively with regulatory agencies to facilitate the approval of innovative formulations that utilize novel excipients and advanced analytical technologies.

6. Conclusions and prospects

Since the COVID-19 pandemic, there has been a marked increase in interest in RNA-LNPs, which has led to a heightened focus on lyophilization as a means to enhance biological stability. Lyophilization transforms liquid formulations into solid drug products through a series of processes, including freezing, primary drying, and secondary drying via sublimation. However, the freezing and drying stages impose significant stresses on biologicals, with freezing-induced stresses arising from low temperatures, cold denaturation, concentration effects, ice-water interface formation, changes in ionic strength, pH shifts, and phase separation, largely due to localized environmental changes. During the drying phase, dehydration is the primary stress factor, as water plays a crucial role in maintaining biological stability. To mitigate these challenges, stabilizers are employed to enhance the stability of biologicals during both processing and storage. These stabilizers can be categorized based on their physicochemical properties into sugars, polyols, amino acids, polymers, and surfactants, with ongoing research dedicated to developing novel stabilizing agents. The optimization of biological formulations will increasingly leverage both traditional approaches, such as DoE and QbD, alongside emerging strategies that utilize AI/ML and digital twins. Future perspectives should focus on enhancing the understanding of structure-stability relationships and the development of next-generation stabilizers that can withstand lyophilization stresses more effectively. Additionally, the optimization process must encompass comprehensive control from the liquid formulation stage through to the final powdered product, ensuring stability during storage and transportation. Continued research on complex formulations, such as CGT and ADC, will be critical as the industry moves toward adopting new modalities and continuous manufacturing techniques. This shift promises significant economic, technological, and regulatory advantages, facilitating the rapid advancement of lyophilization processes and enhancing the overall efficacy and accessibility of biopharmaceutical products.

CRediT authorship contribution statement

Ravi Maharjan: Writing – review & editing, Writing – original draft, Visualization, Investigation, Data curation, Conceptualization. Chang Yell Shin: Visualization. Seon-Kwang Lee: Methodology. Eun-Sol Ha: Methodology. Heejun Park: Methodology. Jeong-Soo Kim: Methodology. Ki Hyun Kim: Methodology. Nam Ah. Kim: Methodology. Min-Soo Kim: Visualization. Seong Hoon Jeong: Writing – review & editing, Funding acquisition, Conceptualization.

Funding

This study was supported by the Technology Innovation Program (RS-2024-00438659; Development of New Materials for Stabilizing Formulations for Freeze-Drying Nucleic Acid Therapeutics), funded by the Ministry of Trade, Industry and Energy (MOTIE, Korea), and by the Yonsei University Research Fund (2025-22-0161).

Declaration of competing interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Seong Hoon Jeong reports was provided by Yonsei University. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

All images in this article are created by BioRender.

Contributor Information

Ravi Maharjan, Email: ravimaharjan@yonsei.ac.kr.

Chang Yell Shin, Email: pharm91@donga.co.kr.

Seon-Kwang Lee, Email: lsk7079@pusan.ac.kr.

Eun-Sol Ha, Email: edel@pusan.ac.kr.

Heejun Park, Email: heejunpark@duksung.ac.kr.

Jeong-Soo Kim, Email: jskim81@duksung.ac.kr.

Ki Hyun Kim, Email: kihyunkim@mnu.ac.kr.

Nam Ah. Kim, Email: namahk87@mnu.ac.kr.

Min-Soo Kim, Email: minsookim@pusan.ac.kr.

Seong Hoon Jeong, Email: ricjeong@yonsei.ac.kr.

Data availability

No data was used for the research described in the article.

References

  1. Abla K.K., Mehanna M.M. Freeze-drying: a flourishing strategy to fabricate stable pharmaceutical and biological products. Int. J. Pharm. 2022;628 doi: 10.1016/j.ijpharm.2022.122233. [DOI] [PubMed] [Google Scholar]
  2. AboulFotouh K., Southard B., Dao H.M., Xu H., Moon C., Williams R.O., III, Cui Z. Effect of lipid composition on RNA-Lipid nanoparticle properties and their sensitivity to thin-film freezing and drying. Int. J. Pharm. 2024;650 doi: 10.1016/j.ijpharm.2023.123688. [DOI] [PubMed] [Google Scholar]
  3. Adali M.B., Barresi A.A., Boccardo G., Pisano R. Spray freeze-drying as a solution to continuous manufacturing of pharmaceutical products in bulk. Processes. 2020;8:709. [Google Scholar]
  4. Ahammad S.R., Narayanasamy D. Development of a stable lyophilized cyclophosphamide monohydrate formulation using non-aqueous solvents. AAPS PharmSciTech. 2024;25:200. doi: 10.1208/s12249-024-02920-9. [DOI] [PubMed] [Google Scholar]
  5. Ai L., Li Y., Zhou L., Yao W., Zhang H., Hu Z., Han J., Wang W., Wu J., Xu P. Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2. Cell Discov. 2023;9:9. doi: 10.1038/s41421-022-00517-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Alejo T., Toro-Córdova A., Fernández L., Rivero A., Stoian A.M., Pérez L., Navarro V., Martínez-Oliván J., de Miguel D. Comprehensive optimization of a freeze-drying process achieving enhanced long-term stability and in vivo performance of lyophilized mRNA-LNPs. Int. J. Mol. 2024;25:10603. doi: 10.3390/ijms251910603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Altay Benetti A., Tan E.Y.Z., Chang Z.W., Bae K.H., Thwin M.T., Muthuramalingam R.P.K., Liao K.-C., Wan Y., Ng L.F., Renia L. Design and characterization of a new formulation for the delivery of COVID-19-mRNA vaccine to the nasal mucosa. Vaccines. 2024;12:409. doi: 10.3390/vaccines12040409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ammann C. Stability studies needed to define the handling and transport conditions of sensitive pharmaceutical or biotechnological products. AAPS PharmSciTech. 2011;12:1264–1275. doi: 10.1208/s12249-011-9684-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Anoud M., Delagoutte E., Helleu Q., Brion A., Duvernois-Berthet E., As M., Marques X., Lamribet K., Senamaud-Beaufort C., Jourdren L., Adrait A., Heinrich S., Toutirais G., Hamlaoui S., Gropplero G., Giovannini I., Ponger L., Geze M., Blugeon C., Couté Y., Guidetti R., Rebecchi L., Giovannangeli C., De Cian A., Concordet J.-P. Comparative transcriptomics reveal a novel tardigrade-specific DNA-binding protein induced in response to ionizing radiation. eLife. 2024;13 doi: 10.7554/eLife.92621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Arakawa T., Tsumoto K., Kita Y.a., Chang B., Ejima D. Biotechnology applications of amino acids in protein purification and formulations. Amino Acids. 2007;33:587–605. doi: 10.1007/s00726-007-0506-3. [DOI] [PubMed] [Google Scholar]
  11. Arpagaus C. Spray Drying of Vaccines: From LABORATORY RESEARCH TO INDUSTRIAL APPLICATIONS. Springer; 2023. Conclusions and future perspectives of spray-dried vaccines; pp. 531–589. [Google Scholar]
  12. Assegehegn G., Brito-de la Fuente E., Franco J.M., Gallegos C. An experimental-based approach to construct the process design space of a freeze-drying process: an effective tool to design an optimum and robust freeze-drying process for pharmaceuticals. J. Pharm. Sci. 2020;109:785–796. doi: 10.1016/j.xphs.2019.07.001. [DOI] [PubMed] [Google Scholar]
  13. Authelin J.-R., Rodrigues M.A., Tchessalov S., Singh S.K., McCoy T., Wang S., Shalaev E. Freezing of biologicals revisited: scale, stability, excipients, and degradation stresses. J. Pharm. Sci. 2020;109:44–61. doi: 10.1016/j.xphs.2019.10.062. [DOI] [PubMed] [Google Scholar]
  14. Bae S.-H., Yoo S., Lee J., Park H.-J., Kwon S.P., Jin H., Park S.-I., Lee Y.-S., Bang Y.-J., Roh G., Lee S., Youn S.B., Kim I.W., Oh H.R., El-Damasy A.K., Keum G., Kim H., Youn H., Nam J.-H., Bang E.-K. A lipid nanoparticle platform incorporating trehalose glycolipid for exceptional mRNA vaccine safety. Bioact. Mater. 2024;38:486–498. doi: 10.1016/j.bioactmat.2024.05.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Bajrovic I., Schafer S.C., Romanovicz D.K., Croyle M.A. Novel technology for storage and distribution of live vaccines and other biological medicines at ambient temperature. Sci. Adv. 2020;6:eaau4819. doi: 10.1126/sciadv.aau4819. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Ball R.L., Bajaj P., Whitehead K.A. Achieving long-term stability of lipid nanoparticles: examining the effect of pH, temperature, and lyophilization. Int. J. Nanomedicine. 2017:305–315. doi: 10.2147/IJN.S123062. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Bharmoria P., Tietze A.A., Mondal D., Kang T.S., Kumar A., Freire M.G. Do ionic liquids exhibit the required characteristics to dissolve, extract, stabilize, and purify proteins? Past-present-future assessment. Chem. Rev. 2024;124:3037–3084. doi: 10.1021/acs.chemrev.3c00551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Bhujel R., Enkmann V., Burgstaller H., Maharjan R. Artificial intelligence-driven strategies for targeted delivery and enhanced stability of RNA-based lipid nanoparticle cancer vaccines. Pharmaceutics. 2025;17:992. doi: 10.3390/pharmaceutics17080992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Bjelošević M., Zvonar Pobirk A., Planinšek O., Ahlin Grabnar P. Excipients in freeze-dried biopharmaceuticals: contributions toward formulation stability and lyophilisation cycle optimisation. Int. J. Pharm. 2020;576 doi: 10.1016/j.ijpharm.2020.119029. [DOI] [PubMed] [Google Scholar]
  20. Bodzen A., Jossier A., Dupont S., Mousset P.-Y., Beney L., Lafay S., Gervais P. Design of a new lyoprotectant increasing freeze-dried Lactobacillus strain survival to long-term storage. BMC Biotechnol. 2021;21:66. doi: 10.1186/s12896-021-00726-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Bogner R., Gong E., Kessler W., Hinds M., Manchanda A., Yoon S., Liu H., Marx R., Zhao J., Sharma P., Bhambhani A., Stanbro J., Alexeenko A., Kazarin P. A Software tool for lyophilization primary drying process development and scale-up including process heterogeneity, I: laboratory-scale model testing. AAPS PharmSciTech. 2021;22:274. doi: 10.1208/s12249-021-02134-3. [DOI] [PubMed] [Google Scholar]
  22. Bolje A., Gobec S. Pharmaceutics. 2021. Analytical techniques for structural characterization of proteins in solid pharmaceutical forms: an overview. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Breen E., Curley J., Overcashier D., Hsu C., Shire S. Effect of moisture on the stability of a lyophilized humanized monoclonal antibody formulation. Pharm. Res. 2001;18:1345–1353. doi: 10.1023/a:1013054431517. [DOI] [PubMed] [Google Scholar]
  24. Brosig S., Cucuzza S., Serno T., Bechtold-Peters K., Buecheler J., Zivec M., Germershaus O., Gallou F. Not the usual suspects: alternative surfactants for biopharmaceuticals. ACS Appl. Mater. Interfaces. 2023;15:34540–34553. doi: 10.1021/acsami.3c05610. [DOI] [PubMed] [Google Scholar]
  25. Brouckaert D., De Meyer L., Vanbillemont B., Van Bockstal P.-J., Lammens J., Mortier S., Corver J., Vervaet C., Nopens I., De Beer T. Potential of near-infrared chemical imaging as process analytical technology tool for continuous freeze-drying. Anal. Chem. 2018;90:4354–4362. doi: 10.1021/acs.analchem.7b03647. [DOI] [PubMed] [Google Scholar]
  26. Butreddy A., Janga K.Y., Ajjarapu S., Sarabu S., Dudhipala N. Instability of therapeutic proteins—an overview of stresses, stabilization mechanisms and analytical techniques involved in lyophilized proteins. Int. J. Biol. Macromol. 2021;167:309–325. doi: 10.1016/j.ijbiomac.2020.11.188. [DOI] [PubMed] [Google Scholar]
  27. Cao Y., He Z., Chen Q., He X., Su L., Yu W., Zhang M., Yang H., Huang X., Li J. Helper-polymer based five-element nanoparticles (FNPs) for lung-specific mRNA delivery with long-term stability after lyophilization. Nano Lett. 2022;22:6580–6589. doi: 10.1021/acs.nanolett.2c01784. [DOI] [PubMed] [Google Scholar]
  28. Capozzi L.C., Trout B.L., Pisano R. From batch to continuous: freeze-drying of suspended vials for pharmaceuticals in unit-doses. Ind. Eng. Chem. Res. 2019;58:1635–1649. [Google Scholar]
  29. Ceresa C., Fracchia L., Sansotera A.C., De Rienzo M.A.D., Banat I.M. Harnessing the potential of biosurfactants for biomedical and pharmaceutical applications. Pharmaceutics. 2023;15:2156. doi: 10.3390/pharmaceutics15082156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Chang B.S., Kendrick B.S., Carpenter J.F. Surface-induced denaturation of proteins during freezing and its inhibition by surfactants. J. Pharm. Sci. 1996;85:1325–1330. doi: 10.1021/js960080y. [DOI] [PubMed] [Google Scholar]
  31. Chang L.L., Shepherd D., Sun J., Tang X.C., Pikal M.J. Effect of sorbitol and residual moisture on the stability of lyophilized antibodies: implications for the mechanism of protein stabilization in the solid state. J. Pharm. Sci. 2005;94:1445–1455. doi: 10.1002/jps.20363. [DOI] [PubMed] [Google Scholar]
  32. Chauhan S.B., Tarkar P.S., Jain C., Singh I. Pullulan as a precision stabilizer in biopharmaceutical lyophilization: a multifunctional excipient shaping the future of biopharmaceutical stability. Polym. Bull. 2026;83:46. [Google Scholar]
  33. Cheng Y., Duong H.T.T., Hu Q., Shameem M., Tang X. Practical advice in the development of a lyophilized protein drug product. Antib. Ther. 2025;8:13–25. doi: 10.1093/abt/tbae030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Chithrani B.D., Ghazani A.A., Chan W.C. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 2006;6:662–668. doi: 10.1021/nl052396o. [DOI] [PubMed] [Google Scholar]
  35. Cho E., Mayhugh B.M., Srinivasan J.M., Sacha G.A., Nail S.L., Topp E.M. Stability of antibody drug conjugate formulations evaluated using solid-state hydrogen-deuterium exchange mass spectrometry. J. Pharm. Sci. 2021;110:2379–2385. doi: 10.1016/j.xphs.2021.03.006. [DOI] [PubMed] [Google Scholar]
  36. Danishuddin, Jamal M.S., Song K.-S., Lee K.-W., Kim J.-J., Park Y.-M. Revolutionizing drug targeting strategies: integrating artificial intelligence and structure-based methods in PROTAC development. Pharmaceuticals. 2023;16 doi: 10.3390/ph16121649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Davidson P., Sun W.Q. Effect of sucrose/raffinose mass ratios on the stability of co-lyophilized protein during storage above the Tg. Pharm. Res. 2001;18:474–479. doi: 10.1023/a:1011002326825. [DOI] [PubMed] [Google Scholar]
  38. De Beer T., Vercruysse P., Burggraeve A., Quinten T., Ouyang J., Zhang X., Vervaet C., Remon J.P., Baeyens W. In-line and real-time process monitoring of a freeze drying process using Raman and NIR spectroscopy as complementary process analytical technology (PAT) tools. J. Pharm. Sci. 2009;98:3430–3446. doi: 10.1002/jps.21633. [DOI] [PubMed] [Google Scholar]
  39. De Leo V., Maurelli A.M., Giotta L., Catucci L. Liposomes containing nanoparticles: preparation and applications. Colloids Surf. B: Biointerfaces. 2022;218 doi: 10.1016/j.colsurfb.2022.112737. [DOI] [PubMed] [Google Scholar]
  40. Degobert G., Aydin D. Lyophilization of nanocapsules: instability sources, formulation and process parameters. Pharmaceutics. 2021;13:1112. doi: 10.3390/pharmaceutics13081112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Duddu S.P., Dal Monte P.R. Effect of glass transition temperature on the stability of lyophilized formulations containing a chimeric therapeutic monoclonal antibody. Pharm. Res. 1997;14:591–595. doi: 10.1023/a:1012144810067. [DOI] [PubMed] [Google Scholar]
  42. Elsayed A., Jaber N., Al-Remawi M., Abu-Salah K. From cell factories to patients: Stability challenges in biopharmaceuticals manufacturing and administration with mitigation strategies. Int. J. Pharm. 2023;645 doi: 10.1016/j.ijpharm.2023.123360. [DOI] [PubMed] [Google Scholar]
  43. Emami F., Keihan Shokooh M., Mostafavi Yazdi S.J. Recent progress in drying technologies for improving the stability and delivery efficiency of biopharmaceuticals. J. Pharm. Investig. 2023;53:35–57. doi: 10.1007/s40005-022-00610-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Fan Y., Rigas D., Kim L.J., Chang F.-P., Zang N., McKee K., Kemball C.C., Yu Z., Winkler P., Su W.-C. Physicochemical and structural insights into lyophilized mRNA-LNP from lyoprotectant and buffer screenings. J. Control. Release. 2024;373:727–737. doi: 10.1016/j.jconrel.2024.07.052. [DOI] [PubMed] [Google Scholar]
  45. Fissore D., Pisano R., Barresi A.A. On the methods based on the Pressure Rise Test for monitoring a freeze-drying process. Dry. Technol. 2010;29:73–90. [Google Scholar]
  46. Fonte P., Reis S., Sarmento B. Facts and evidences on the lyophilization of polymeric nanoparticles for drug delivery. J. Control. Release. 2016;225:75–86. doi: 10.1016/j.jconrel.2016.01.034. [DOI] [PubMed] [Google Scholar]
  47. Forney-Stevens K.M., Bogner R.H., Pikal M.J. Addition of amino acids to further stabilize lyophilized sucrose-based protein formulations: I. Screening of 15 amino acids in two model proteins. J. Pharm. Sci. 2016;105:697–704. doi: 10.1002/jps.24655. [DOI] [PubMed] [Google Scholar]
  48. Fu Z., Li S., Han S., Shi C., Zhang Y. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct. Target. Ther. 2022;7:93. doi: 10.1038/s41392-022-00947-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Gatto M.S., Najahi-Missaoui W. Lyophilization of nanoparticles, does it really work? Overview of the current status and challenges. Int. J. Mol. Sci. 2023;24:14041. doi: 10.3390/ijms241814041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Goldman J.M., More H.T., Yee O., Borgeson E., Remy B., Rowe J., Sadineni V. Optimization of primary drying in lyophilization during early-phase drug development using a definitive screening design with formulation and process factors. J. Pharm. Sci. 2018;107:2592–2600. doi: 10.1016/j.xphs.2018.06.001. [DOI] [PubMed] [Google Scholar]
  51. Gomes V., Salgueiro S.P. From small to large-scale: a review of recombinant spider silk and collagen bioproduction. Discov. Mater. 2022;2:3. [Google Scholar]
  52. Gomez M., Vehring R. Spray drying and particle engineering in dosage form design for global vaccines. J. Aerosol. Med. Pulm. Drug Deliv. 2022;35:121–138. doi: 10.1089/jamp.2021.0056. [DOI] [PubMed] [Google Scholar]
  53. Groël S., Menzen T., Winter G. Pharmaceutics. 2023. Prediction of unwanted crystallization of freeze-dried protein formulations using α-relaxation measurements. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Haeuser C., Goldbach P., Huwyler J., Friess W., Allmendinger A. Impact of dextran on thermal properties, product quality attributes, and monoclonal antibody stability in freeze-dried formulations. Eur. J. Pharm. Biopharm. 2020;147:45–56. doi: 10.1016/j.ejpb.2019.12.010. [DOI] [PubMed] [Google Scholar]
  55. Hardianto A., Muscifa Z.S., Widayat W., Yusuf M., Subroto T. The effect of ethanol on lipid nanoparticle stabilization from a molecular dynamics simulation perspective. Molecules. 2023;28:4836. doi: 10.3390/molecules28124836. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Herrmann A., Abbina S., Bathula N.V., Nouri P.M.M., Chafeeva I., Constantinescu I., Abbasi E., Abbasi U., Drayton M., Luo H.D. An ultrahydrating polymer that protects protein therapeutics and RNA-lipid nanoparticles against freezing, heat and lyophilization stress. Adv. Funct. Mater. 2024;34:2406878. [Google Scholar]
  57. Heyndrickx W., Mervin L., Morawietz T., Sturm N., Friedrich L., Zalewski A., Pentina A., Humbeck L., Oldenhof M., Niwayama R., Schmidtke P., Fechner N., Simm J., Arany A., Drizard N., Jabal R., Afanasyeva A., Loeb R., Verma S., Harnqvist S., Holmes M., Pejo B., Telenczuk M., Holway N., Dieckmann A., Rieke N., Zumsande F., Clevert D.-A., Krug M., Luscombe C., Green D., Ertl P., Antal P., Marcus D., Do Huu N., Fuji H., Pickett S., Acs G., Boniface E., Beck B., Sun Y., Gohier A., Rippmann F., Engkvist O., Göller A.H., Moreau Y., Galtier M.N., Schuffenhauer A., Ceulemans H. MELLODDY: cross-pharma federated learning at unprecedented scale unlocks benefits in QSAR without compromising proprietary information. J. Chem. Inf. Model. 2024;64:2331–2344. doi: 10.1021/acs.jcim.3c00799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Holm T.P., Meng-Lund H., Rantanen J., Jorgensen L., Grohganz H. Screening of novel excipients for freeze-dried protein formulations. Eur. J. Pharm. Biopharm. 2021;160:55–64. doi: 10.1016/j.ejpb.2021.01.008. [DOI] [PubMed] [Google Scholar]
  59. Horn J., Friess W. Detection of collapse and crystallization of saccharide, protein, and mannitol formulations by optical fibers in lyophilization. Front. Chem. 2018;6:4. doi: 10.3389/fchem.2018.00004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Hosseinpour S., Cao Y., Liu J., Xu C., Walsh L.J. Efficient transfection and long-term stability of rno-miRNA-26a-5p for osteogenic differentiation by large pore sized mesoporous silica nanoparticles. J. Mater. Chem. B. 2021;9:2275–2284. doi: 10.1039/d0tb02756a. [DOI] [PubMed] [Google Scholar]
  61. Howard M.D., Lu X., Jay M., Dziubla T.D. Optimization of the lyophilization process for long-term stability of solid–lipid nanoparticles. Drug Dev. Ind. Pharm. 2012;38:1270–1279. doi: 10.3109/03639045.2011.645835. [DOI] [PubMed] [Google Scholar]
  62. Hubbard R.E., Haider M.K. Encyclopedia of Life Sciences. Vol. 1. 2010. Hydrogen bonds in proteins: role and strength; pp. 1–6. [Google Scholar]
  63. Hung C.-L., Kuo Y.-H., Lee S.W., Chiang Y.-W. Protein stability depends critically on the surface hydrogen-bonding network: A case study of Bid protein. J. Phys. Chem. B. 2021;125:8373–8382. doi: 10.1021/acs.jpcb.1c03245. [DOI] [PubMed] [Google Scholar]
  64. Ilić-Stojanović S., Cakić S., Nikolić N., Petrović S. Innovative and patented liposome-based drug carriers. Processes. 2024;12:1970. [Google Scholar]
  65. Imamura K., Murai K., Korehisa T., Shimizu N., Yamahira R., Matsuura T., Tada H., Imanaka H., Ishida N., Nakanishi K. Characteristics of sugar surfactants in stabilizing proteins during freeze–thawing and freeze–drying. J. Pharm. Sci. 2014;103:1628–1637. doi: 10.1002/jps.23988. [DOI] [PubMed] [Google Scholar]
  66. Izutsu K.-I., Fujimaki Y., Kuwabara A., Aoyagi N. Effect of counterions on the physical properties of l-arginine in frozen solutions and freeze-dried solids. Int. J. Pharm. 2005;301:161–169. doi: 10.1016/j.ijpharm.2005.05.019. [DOI] [PubMed] [Google Scholar]
  67. Jameel F., Alexeenko A., Bhambhani A., Sacha G., Zhu T., Tchessalov S., Kumar L., Sharma P., Moussa E., Iyer L. Recommended best practices for lyophilization validation—2021 part I: process design and modeling. AAPS PharmSciTech. 2021;22:221. doi: 10.1208/s12249-021-02086-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Jeon B.-J., Guareschi M.M., Stewart J.M., Wu E., Gopinath A., Arroyo-Currás N., Dauphin-Ducharme P., Plaxco K.W., Lukeman P.S., Rothemund P.W. Modular DNA origami–based electrochemical detection of DNA and proteins. Proc. Natl. Acad. Sci. 2025;122 doi: 10.1073/pnas.2311279121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Jiang M., Sieber-Schäfer F., Carneiro S.P., Matzek D., Nguyen A., Porras-Gonzalez D.L., Verma A.K., Kolog-Gulko M., Jürgens D.C., Burgstaller G. A hybrid polymeric system for pulmonary mRNA delivery: advancing mucosal vaccine development. Cell. 2026;2:100311. doi: 10.1016/j.celbio.2025.100311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Juckers A., Knerr P., Harms F., Strube J. Emerging PAT for freeze-drying processes for advanced process control. Processes. 2022;10:2059. [Google Scholar]
  71. Jun T., Shin S.-H., Won Y.-Y. Engineered polymeric excipients for enhancing the stability of protein biologics: poly (N-isopropylacrylamide)-poly (ethylene glycol)(PNIPAM-PEG) block copolymers. Int. J. Pharm. 2024;664 doi: 10.1016/j.ijpharm.2024.124636. [DOI] [PubMed] [Google Scholar]
  72. Kafle U., Truong H.Q., Nguyen C.T.G., Meng F. Development of thermally stable mRNA-LNP delivery systems: current progress and future prospects. Mol. Pharm. 2024;21:5944–5959. doi: 10.1021/acs.molpharmaceut.4c00826. [DOI] [PubMed] [Google Scholar]
  73. Kalinke I., Unterbuchberger G., Kulozik U. Enhancing drying efficiency and temperature uniformity during microwave-assisted freeze drying: a weight-dependent microwave power approach. J. Food Eng. 2025;406:112810. [Google Scholar]
  74. Karunnanithy V., Abdul Rahman N.H., Abdullah N.A., Fauzi M.B., Lokanathan Y., Min Hwei A.N., Maarof M. Effectiveness of lyoprotectants in protein stabilization during lyophilization. Pharmaceutics. 2024;16:1346. doi: 10.3390/pharmaceutics16101346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Kasianchuk N., Rzymski P., Kaczmarek Ł. The biomedical potential of tardigrade proteins: a review. Biomed. Pharmacother. 2023;158 doi: 10.1016/j.biopha.2022.114063. [DOI] [PubMed] [Google Scholar]
  76. Kasper J.C., Friess W. The freezing step in lyophilization: physico-chemical fundamentals, freezing methods and consequences on process performance and quality attributes of biopharmaceuticals. Eur. J. Pharm. Biopharm. 2011;78:248–263. doi: 10.1016/j.ejpb.2011.03.010. [DOI] [PubMed] [Google Scholar]
  77. Katz J.S., Chou D.K., Christian T.R., Das T.K., Patel M., Singh S.N., Wen Y. Emerging challenges and innovations in surfactant-mediated stabilization of biologic formulations. J. Pharm. Sci. 2022;111:919–932. doi: 10.1016/j.xphs.2021.12.002. [DOI] [PubMed] [Google Scholar]
  78. Kawasaki H., Shimanouchi T., Kimura Y. Recent development of optimization of lyophilization process. J. Chemother. 2019;2019:9502856. [Google Scholar]
  79. Khan M.F., Youssef M., Nesdoly S., Kamen A.A. Development of robust freeze-drying process for long-term stability of rVSV-SARS-CoV-2 vaccine. Viruses. 2024;16:942. doi: 10.3390/v16060942. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Kim H.L., Mcauley A., Livesay B., Gray W.D., Mcguire J. Modulation of protein adsorption by poloxamer 188 in relation to polysorbates 80 and 20 at solid surfaces. J. Pharm. Sci. 2014;103:1043–1049. doi: 10.1002/jps.23907. [DOI] [PubMed] [Google Scholar]
  81. Kim B., Hosn R.R., Remba T., Yun D., Li N., Abraham W., Melo M.B., Cortes M., Li B., Zhang Y. Optimization of storage conditions for lipid nanoparticle-formulated self-replicating RNA vaccines. J. Control. Release. 2023;353:241–253. doi: 10.1016/j.jconrel.2022.11.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Kim U.-I., Maharjan R., Han H.-K., Kim K., Jeong S.H. Formulation development of basroparib as a first-in-class tankyrase inhibitor using a microprecipitated bulk powder approach. J. Pharm. Investig. 2025;56:331–341. [Google Scholar]
  83. King C.J. Google Patents; 1976. Controlled humidity freeze drying process. [Google Scholar]
  84. Klepzig L.S., Juckers A., Knerr P., Harms F., Strube J. Digital twin for lyophilization by process modeling in manufacturing of biologics. Processes. 2020;8:1325. [Google Scholar]
  85. Klink T.A., Woycechowsky K.J., Taylor K.M., Raines R.T. Contribution of disulfide bonds to the conformational stability and catalytic activity of ribonuclease A. Eur. J. Biochem. 2000;267:566–572. doi: 10.1046/j.1432-1327.2000.01037.x. [DOI] [PubMed] [Google Scholar]
  86. Kombo D.C., LaMarche M.J., Konkankit C.C., Rackovsky S. Application of artificial intelligence and machine learning techniques to the analysis of dynamic protein sequences. Proteins Struct. Funct. Bioinf. 2024;92:1234–1241. doi: 10.1002/prot.26704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Kristiansen J. Leakage of a trapped fluorescent marker from liposomes: effects of eutectic crystallization of NaCl and internal freezing. Cryobiology. 1992;29:575–584. doi: 10.1016/0011-2240(92)90062-7. [DOI] [PubMed] [Google Scholar]
  88. Kumar S., Sanap S.N., Vasoya M., Handa M., Pandey P., Khopade A., Sawant K.K. USFDA-approved parenteral peptide formulations and excipients: industrial perspective. J. Drug Delivery Sci. Technol. 2024;95 [Google Scholar]
  89. Leys L., Vanbillemont B., Van Bockstal P.-J., Lammens J., Nuytten G., Corver J., Vervaet C., De Beer T. A primary drying model-based comparison of conventional batch freeze-drying to continuous spin-freeze-drying for unit doses. Eur. J. Pharm. Biopharm. 2020;157:97–107. doi: 10.1016/j.ejpb.2020.09.009. [DOI] [PubMed] [Google Scholar]
  90. Li M., Jia L., Xie Y., Ma W., Yan Z., Liu F., Deng J., Zhu A., Siwei X., Su W. Lyophilization process optimization and molecular dynamics simulation of mRNA-LNPs for SARS-CoV-2 vaccine. npj Vaccin. 2023;8 doi: 10.1038/s41541-023-00732-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Li J., Wang H., Wang L., Yu D., Zhang X. Stabilization effects of saccharides in protein formulations: a review of sucrose, trehalose, cyclodextrins and dextrans. Eur. J. Pharm. Sci. 2024;192 doi: 10.1016/j.ejps.2023.106625. [DOI] [PubMed] [Google Scholar]
  92. Li Q., Shi R., Xu H., AboulFotouh K., Sung M.M., Oguin T.H., Hayes M., Moon C., Dao H.M., Ni H. Thin-film freeze-drying of an influenza virus hemagglutinin mRNA vaccine in unilamellar lipid nanoparticles with blebs. J. Control. Release. 2024;375:829–838. doi: 10.1016/j.jconrel.2024.09.030. [DOI] [PubMed] [Google Scholar]
  93. Li W., Wang T., Chen J., Guo M., Ling L., Higuchi A. Application of saccharide cryoprotectants in the freezing or lyophilization process of lipid nanoparticles encapsulating gene drugs for regenerative medicine. Regen. Med. Dent. 2024:3. [Google Scholar]
  94. Liang L., Carrigy N.B., Kariuki S., Muturi P., Onsare R., Nagel T., Vehring R., Connerton P.L., Connerton I.F. Development of a lyophilization process for campylobacter bacteriophage storage and transport. Microorganism. 2020;8:282. doi: 10.3390/microorganisms8020282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Lietta E., Colucci D., Distefano G., Fissore D. On the use of infrared thermography for monitoring a vial freeze-drying process. J. Pharm. Sci. 2019;108:391–398. doi: 10.1016/j.xphs.2018.07.025. [DOI] [PubMed] [Google Scholar]
  96. Lim J.Y., Lim D.G., Kim K.H., Park S.-K., Jeong S.H. Effects of annealing on the physical properties of therapeutic proteins during freeze drying process. Int. J. Biol. Macromol. 2018;107:730–740. doi: 10.1016/j.ijbiomac.2017.09.041. [DOI] [PubMed] [Google Scholar]
  97. Lin M., Cao H., Li J. Control strategies of ice nucleation, growth, and recrystallization for cryopreservation. Acta Biomater. 2023;155:35–56. doi: 10.1016/j.actbio.2022.10.056. [DOI] [PubMed] [Google Scholar]
  98. Liu Y., Zhang S., Wang S., Zhang C., Su X., Guo L., Bai X., Huang Y., Pang W., Tan F. Screening and stability evaluation of freeze-dried protective agents for a live recombinant pseudorabies virus vaccine. Vaccines. 2024;12:65. doi: 10.3390/vaccines12010065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Luo W.-C., Beringhs A.O.R., Kim R., Zhang W., Patel S.M., Bogner R.H., Lu X. Impact of formulation on the quality and stability of freeze-dried nanoparticles. Eur. J. Pharm. Biopharm. 2021;169:256–267. doi: 10.1016/j.ejpb.2021.10.014. [DOI] [PubMed] [Google Scholar]
  100. Maharjan R., Jeong S.H. Application of different models to evaluate the key factors of fluidized bed layering granulation and their influence on granule characteristics. Powder Technol. 2022;408 [Google Scholar]
  101. Maharjan R., Lee J.C., Kim N.A., Jeong S.H. Preparation of seeded granules to improve mechanical properties and various drug loading for pharmaceutical application. Powder Technol. 2021;392:650–660. [Google Scholar]
  102. Maharjan R., Jeong J., Bhujel R., Kim M.-S., Han H.-K., Kim N.A., Jeong S.H. Correlation of solubility thermodynamics of Glibenclamide with recrystallization and in vitro release profile. Molecules. 2022;27:1392. doi: 10.3390/molecules27041392. [DOI] [PMC free article] [PubMed] [Google Scholar]
  103. Maharjan R., Hada S., Lee J.E., Han H.-K., Kim K.H., Seo H.J., Foged C., Jeong S.H. Comparative study of lipid nanoparticle-based mRNA vaccine bioprocess with machine learning and combinatorial artificial neural network-design of experiment approach. Int. J. Pharm. 2023;640 doi: 10.1016/j.ijpharm.2023.123012. [DOI] [PubMed] [Google Scholar]
  104. Maharjan R., Lee J.C., Lee K., Han H.-K., Kim K.H., Jeong S.H. Recent trends and perspectives of artificial intelligence-based machine learning from discovery to manufacturing in biopharmaceutical industry. J. Pharm. Investig. 2023;53:803–826. [Google Scholar]
  105. Maharjan R., Kim K.H., Lee K., Han H.-K., Jeong S.H. Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost/Bayesian method and ensemble model approaches. J. Pharm. Anal. 2024;14 doi: 10.1016/j.jpha.2024.100996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Maharjan R., Lee J.C., Bøtker J.P., Kim K.H., Kim N.A., Jeong S.H., Rantanen J. Assessment of subvisible particles in biopharmaceuticals with image feature extraction and machine learning. Chemom. Intell. Lab. Syst. 2024;245 [Google Scholar]
  107. Maharjan R., Lim D.S., Baik H.J., Park H.E., Kim M.-S., Kim K.H., Jeong S.H. Preparation of semaglutide long-acting injectable microcapsules with physicochemical properties, long-term stability, and pharmacokinetics and pharmacodynamics. J. Pharm. Investig. 2024;54:667–681. [Google Scholar]
  108. Maharjan R., Kim N.A., Kim K.H., Jeong S.H. Transformative roles of digital twins from drug discovery to continuous manufacturing: pharmaceutical and biopharmaceutical perspectives. Int. J. Pharmaceut. X. 2025;10 doi: 10.1016/j.ijpx.2025.100409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  109. Mehanna M.M., Abla K.K. Recent advances in freeze-drying: variables, cycle optimization, and innovative techniques. Pharm. Dev. Technol. 2022;27:904–923. doi: 10.1080/10837450.2022.2129385. [DOI] [PubMed] [Google Scholar]
  110. Merivaara A., Zini J., Koivunotko E., Valkonen S., Korhonen O., Fernandes F.M., Yliperttula M. Preservation of biomaterials and cells by freeze-drying: change of paradigm. J. Control. Release. 2021;336:480–498. doi: 10.1016/j.jconrel.2021.06.042. [DOI] [PubMed] [Google Scholar]
  111. Meulewaeter S., Aernout I., Deprez J., Engelen Y., De Velder M., Franceschini L., Breckpot K., Van Calenbergh S., Asselman C., Boucher K., Impens F., De Smedt S.C., Verbeke R., Lentacker I. Alpha-galactosylceramide improves the potency of mRNA LNP vaccines against cancer and intracellular bacteria. J. Control. Release. 2024;370:379–391. doi: 10.1016/j.jconrel.2024.04.052. [DOI] [PubMed] [Google Scholar]
  112. Mortier S.T.F., Van Bockstal P.-J., Corver J., Nopens I., Gernaey K.V., De Beer T. Uncertainty analysis as essential step in the establishment of the dynamic design space of primary drying during freeze-drying. Eur. J. Pharm. Biopharm. 2016;103:71–83. doi: 10.1016/j.ejpb.2016.03.015. [DOI] [PubMed] [Google Scholar]
  113. Müller P., Sack A., Dümler J., Heckel M., Wenzel T., Siegert T., Schuldt-Lieb S., Gieseler H., Pöschel T. Automated tomographic assessment of structural defects of freeze-dried pharmaceuticals. AAPS PharmSciTech. 2024;25:143. doi: 10.1208/s12249-024-02833-7. [DOI] [PubMed] [Google Scholar]
  114. Muramatsu H., Lam K., Bajusz C., Laczkó D., Karikó K., Schreiner P., Martin A., Lutwyche P., Heyes J., Pardi N. Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine. Mol. Ther. 2022;30:1941–1951. doi: 10.1016/j.ymthe.2022.02.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  115. Murray A., Kilbride P., Gibson M.I. Trehalose in cryopreservation. Applications, mechanisms and intracellular delivery opportunities. RSC Med. Chem. 2024;15:2980–2995. doi: 10.1039/d4md00174e. [DOI] [PMC free article] [PubMed] [Google Scholar]
  116. Najarian J., Metsi-Guckel E., Renawala H.K., Grosse D., Sims A., Walter A., Sarkar A., Karande A. Optimizing lyophilization primary drying: a vaccine case study with experimental and modeling techniques. Int. J. Pharm. 2024;659 doi: 10.1016/j.ijpharm.2024.124168. [DOI] [PubMed] [Google Scholar]
  117. Nguyen K.T., Zillen D., Lasorsa A., van der Wel P.C., Frijlink H.W., Hinrichs W.L. Combinations of arginine and pullulan reveal the selective effect of stabilization mechanisms on different lyophilized proteins. Int. J. Pharm. 2024;654 doi: 10.1016/j.ijpharm.2024.123938. [DOI] [PubMed] [Google Scholar]
  118. Noverraz F., Robin B., Passemard S., Fauvel B., Presumey J., Rigal E., Cookson A., Chopineau J., Martineau P., Villalba M. Novel trehalose-based excipients for stabilizing nebulized anti-SARS-CoV-2 antibody. Int. J. Pharm. 2023;630 doi: 10.1016/j.ijpharm.2022.122463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  119. Oddone I., Barresi A.A., Pisano R. Influence of controlled ice nucleation on the freeze-drying of pharmaceutical products: the secondary drying step. Int. J. Pharm. 2017;524:134–140. doi: 10.1016/j.ijpharm.2017.03.077. [DOI] [PubMed] [Google Scholar]
  120. Oude Blenke E., Örnskov E., Schöneich C., Nilsson G.A., Volkin D.B., Mastrobattista E., Almarsson Ö., Crommelin D.J. The storage and in-use stability of mRNA vaccines and therapeutics: not a cold case. J. Pharm. Sci. 2023;112:386–403. doi: 10.1016/j.xphs.2022.11.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  121. Öztürk K., Kaplan M., Çalış S. Effects of nanoparticle size, shape, and zeta potential on drug delivery. Int. J. Pharm. 2024;666 doi: 10.1016/j.ijpharm.2024.124799. [DOI] [PubMed] [Google Scholar]
  122. Pal S.L., Jana U., Manna P.K., Mohanta G.P., Manavalan R. Nanoparticle: an overview of preparation and characterization. J. Appl. Pharm. Sci. 2011:228–234. [Google Scholar]
  123. Pardeshi S.R., Deshmukh N.S., Telange D.R., Nangare S.N., Sonar Y.Y., Lakade S.H., Harde M.T., Pardeshi C.V., Gholap A., Deshmukh P.K., More M.P. Process development and quality attributes for the freeze-drying process in pharmaceuticals, biopharmaceuticals and nanomedicine delivery: a state-of-the-art review. Fut. J. Pharm. Sci. 2023;9:99. [Google Scholar]
  124. Patel S.M., Doen T., Pikal M.J. Determination of end point of primary drying in freeze-drying process control. AAPS PharmSciTech. 2010;11:73–84. doi: 10.1208/s12249-009-9362-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  125. Patil C.D., Tejasvi Mutukuri T., Santosh Arte K., Huang Y., Radhakrishnan V., Tony Zhou Q. Effects of buffers on spray-freeze-dried/lyophilized high concentration protein formulations. Int. J. Pharm. 2025;668 doi: 10.1016/j.ijpharm.2024.124974. [DOI] [PubMed] [Google Scholar]
  126. Petkov V., Vinarov Z., Tcholakova S. Mechanisms of dissolution and crystallization of amorphous glibenclamide. Int. J. Pharm. 2024;666 doi: 10.1016/j.ijpharm.2024.124820. [DOI] [PubMed] [Google Scholar]
  127. Pikal M.J., Roy M.L., Shah S. Mass and heat transfer in vial freeze-drying of pharmaceuticals: Role of the vial. J. Pharm. Sci. 1984;73:1224–1237. doi: 10.1002/jps.2600730910. [DOI] [PubMed] [Google Scholar]
  128. Pisano R., Arsiccio A., Capozzi L.C., Trout B.L. Achieving continuous manufacturing in lyophilization: technologies and approaches. Eur. J. Pharm. Biopharm. 2019;142:265–279. doi: 10.1016/j.ejpb.2019.06.027. [DOI] [PubMed] [Google Scholar]
  129. Pochapski D.J., Carvalho dos Santos C., Leite G.W., Pulcinelli S.H., Santilli C.V. Zeta potential and colloidal stability predictions for inorganic nanoparticle dispersions: effects of experimental conditions and electrokinetic models on the interpretation of results. Langmuir. 2021;37:13379–13389. doi: 10.1021/acs.langmuir.1c02056. [DOI] [PubMed] [Google Scholar]
  130. Qiu X., Li H., Ver Steeg G., Godzik A. Advances in AI for protein structure prediction: implications for cancer drug discovery and development. Biomolecules. 2024;14:339. doi: 10.3390/biom14030339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  131. Rafiq Q.A., Nienow A.W., Hewitt C.J., Coopman K. The role of biopreservation in cell and gene therapy bioprocessing. Cell Gene Ther. Insights. 2017;3:335–344. [Google Scholar]
  132. Randolph T.W. Phase separation of excipients during lyophilization: effects on protein stability. J. Pharm. Sci. 1997;86:1198–1203. doi: 10.1021/js970135b. [DOI] [PubMed] [Google Scholar]
  133. Regis F., Arsiccio A., Bourlès E., Scutellà B., Pisano R. Surface treatment of glass vials for lyophilization: implications for vacuum-induced surface freezing. Pharmaceutics. 2021;13:1766. doi: 10.3390/pharmaceutics13111766. [DOI] [PMC free article] [PubMed] [Google Scholar]
  134. Rodrigues M.A., Rego P., Geraldes V., Connor L.E., Oswald I.D., Sztucki M., Shalaev E. Mannitol crystallization at sub-zero temperatures: time/temperature-resolved synchrotron X-ray diffraction study and the phase diagram. J. Phys. Chem. Lett. 2021;12:1453–1460. doi: 10.1021/acs.jpclett.0c03680. [DOI] [PubMed] [Google Scholar]
  135. Roth C., Winter G., Lee G. Continuous measurement of drying rate of crystalline and amorphous systems during freeze-drying using an in situ microbalance technique. J. Pharm. Sci. 2001;90:1345–1355. doi: 10.1002/jps.1087. [DOI] [PubMed] [Google Scholar]
  136. Ruppl A., Kiesewetter D., Strütt F., Köll-Weber M., Süss R., Allmendinger A. Don’t shake it! mechanical stress testing of mRNA-lipid nanoparticles. Eur. J. Pharm. Biopharm. 2024;198 doi: 10.1016/j.ejpb.2024.114265. [DOI] [PubMed] [Google Scholar]
  137. Sahni E.K., Pikal M.J. Modeling the secondary drying stage of freeze drying: development and validation of an excel-based model. J. Pharm. Sci. 2017;106:779–791. doi: 10.1016/j.xphs.2016.10.024. [DOI] [PubMed] [Google Scholar]
  138. Schaal Z., Van Bockstal P.-J., Lammens J., Lenger J.H., Funke A.P., Schneid S.C., Svilenov H.L., De Beer T. Optimization of continuous spin-freeze-drying: the role of spin-freezing on quality attributes and drying efficiency of a model peptide formulation. Eur. J. Pharm. Sci. 2025;204 doi: 10.1016/j.ejps.2024.106963. [DOI] [PubMed] [Google Scholar]
  139. Schiewe M.C., Anderson R.E. Vitrification: the pioneering past to current trends and perspectives of cryopreserving human embryos, gametes and reproductive tissue. J. Biorepository Sci. Appl. Med. 2017:57–68. [Google Scholar]
  140. Schneid S., Gieseler H. Evaluation of a new wireless temperature remote interrogation system (TEMPRIS) to measure product temperature during freeze drying. AAPS PharmSciTech. 2008;9:729–739. doi: 10.1208/s12249-008-9099-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  141. Schneid S.C., Gieseler H., Kessler W.J., Luthra S.A., Pikal M.J. Optimization of the secondary drying step in freeze drying using TDLAS technology. AAPS PharmSciTech. 2011;12:379–387. doi: 10.1208/s12249-011-9600-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  142. Searles J.A., Aravapalli S., Hodge C. Effects of chamber pressure and partial pressure of water vapor on secondary drying in lyophilization. AAPS PharmSciTech. 2017;18:2808–2813. doi: 10.1208/s12249-017-0768-3. [DOI] [PubMed] [Google Scholar]
  143. Serno T., Geidobler R., Winter G. Protein stabilization by cyclodextrins in the liquid and dried state. Adv. Drug Deliv. Rev. 2011;63:1086–1106. doi: 10.1016/j.addr.2011.08.003. [DOI] [PubMed] [Google Scholar]
  144. Sharma A., Khamar D., Cullen S., Hayden A., Hughes H. Innovative drying technologies for biopharmaceuticals. Int. J. Pharm. 2021;609 doi: 10.1016/j.ijpharm.2021.121115. [DOI] [PubMed] [Google Scholar]
  145. Shirane D., Tanaka H., Sakurai Y., Taneichi S., Nakai Y., Tange K., Ishii I., Akita H. Development of an alcohol dilution–lyophilization method for the preparation of mRNA-LNPs with improved storage stability. Pharmaceutics. 2023;15:1819. doi: 10.3390/pharmaceutics15071819. [DOI] [PMC free article] [PubMed] [Google Scholar]
  146. Shivkumar G., Kazarin P.S., Strongrich A.D., Alexeenko A.A. LyoPRONTO: an Open-Source Lyophilization Process Optimization Tool. AAPS PharmSciTech. 2019;20:328. doi: 10.1208/s12249-019-1532-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  147. Siew A. Vol. 42. PharmTech; 2018. Freeze-drying Process Optimization; pp. 18–23. [Google Scholar]
  148. Sikora A., Shard A.G., Minelli C. Size and ζ-potential measurement of silica nanoparticles in serum using tunable resistive pulse sensing. Langmuir. 2016;32:2216–2224. doi: 10.1021/acs.langmuir.5b04160. [DOI] [PubMed] [Google Scholar]
  149. Sivasankaran R.P., Snell K., Kunkel G., Georgiou P.G., Puente E.G., Maynard H.D. Polymer-mediated protein/peptide therapeutic stabilization: current progress and future directions. Prog. Polym. Sci. 2024;156 [Google Scholar]
  150. Song J.G., Lee S.H., Han H.-K. The stabilization of biopharmaceuticals: current understanding and future perspectives. J. Pharm. Investig. 2017;47:475–496. [Google Scholar]
  151. Srisuma P., Barbastathis G., Braatz R.D. Mechanistic modeling and analysis of thermal radiation in conventional, microwave-assisted, and hybrid freeze drying for biopharmaceutical manufacturing. Int. J. Heat Mass Transf. 2024;221 [Google Scholar]
  152. Srisuma P., Barbastathis G., Braatz R.D. Real-time estimation of bound water concentration during lyophilization with temperature-based state observers. Int. J. Pharm. 2024;665 doi: 10.1016/j.ijpharm.2024.124693. [DOI] [PubMed] [Google Scholar]
  153. Stärtzel P. Arginine as an excipient for protein freeze-drying: a mini review. J. Pharm. Sci. 2018;107:960–967. doi: 10.1016/j.xphs.2017.11.015. [DOI] [PubMed] [Google Scholar]
  154. Strambini G.B., Gabellieri E. Proteins in frozen solutions: evidence of ice-induced partial unfolding. Biophys. J. 1996;70:971–976. doi: 10.1016/S0006-3495(96)79640-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  155. Suzuki Y., Miyazaki T., Muto H., Kubara K., Mukai Y., Watari R., Sato S., Kondo K., Tsukumo S.-I., Yasutomo K. Design and lyophilization of lipid nanoparticles for mRNA vaccine and its robust immune response in mice and nonhuman primates. Mol. Ther. Nucleic Acids. 2022;30:226–240. doi: 10.1016/j.omtn.2022.09.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  156. Tambe S., Jain D., Meruva S.K., Rongala G., Juluri A., Nihalani G., Mamidi H.K., Nukala P.K., Bolla P.K. Recent advances in amorphous solid dispersions: preformulation, formulation strategies, technological advancements and characterization. Pharmaceutics. 2022;14:2203. doi: 10.3390/pharmaceutics14102203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  157. Tang X.C., Nail S.L., Pikal M.J. Evaluation of manometric temperature measurement (MTM), a process analytical technology tool in freeze drying, part III: heat and mass transfer measurement. AAPS PharmSciTech. 2006;7:E105–E111. doi: 10.1208/pt070497. [DOI] [PMC free article] [PubMed] [Google Scholar]
  158. Tchessalov S., Maglio V., Kazarin P., Alexeenko A., Bhatnagar B., Sahni E., Shalaev E. Practical advice on scientific design of freeze-drying process: 2023 update. Pharm. Res. 2023;40:2433–2455. doi: 10.1007/s11095-023-03607-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  159. Thakral S., Sonje J., Munjal B., Suryanarayanan R. Stabilizers and their interaction with formulation components in frozen and freeze-dried protein formulations. Adv. Drug Deliv. Rev. 2021;173:1–19. doi: 10.1016/j.addr.2021.03.003. [DOI] [PubMed] [Google Scholar]
  160. Tosstorff A., Menzen T., Winter G. Exploring chemical space for new substances to stabilize a therapeutic monoclonal antibody. J. Pharm. Sci. 2020;109:301–307. doi: 10.1016/j.xphs.2019.10.057. [DOI] [PubMed] [Google Scholar]
  161. Trenkenschuh E., Friess W. Freeze-drying of nanoparticles: how to overcome colloidal instability by formulation and process optimization. Eur. J. Pharm. Biopharm. 2021;165:345–360. doi: 10.1016/j.ejpb.2021.05.024. [DOI] [PubMed] [Google Scholar]
  162. Uddin M.N., Roni M.A. Challenges of storage and stability of mRNA-based COVID-19 vaccines. Vaccines. 2021;9:1033. doi: 10.3390/vaccines9091033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  163. Van Pottelberge R., Matthessen R., Salem S., Goffin B., Oien N., Bharti P., Ripley D. Importance of RNase monitoring during large-scale manufacturing and analysis of mRNA-LNP based vaccines. J. Pharm. Sci. 2025;114:1520–1528. doi: 10.1016/j.xphs.2024.10.012. [DOI] [PubMed] [Google Scholar]
  164. Vanbillemont B., Nicolaï N., Leys L., De Beer T. Model-based optimisation and control strategy for the primary drying phase of a lyophilisation process. Pharmaceutics. 2020;12:181. doi: 10.3390/pharmaceutics12020181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  165. Vanbillemont B., Arsiccio A., Menzen T., Hawe A. Optimization and transfer of robust primary drying protocols for biopharmaceuticals through lyophilization process modeling. AAPS Open. 2025;11:13. [Google Scholar]
  166. Vinciguerra D., Gelb M.B., Maynard H.D. Synthesis and application of trehalose materials. JACS Au. 2022;2:1561–1587. doi: 10.1021/jacsau.2c00309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  167. Voigt E.A., Gerhardt A., Hanson D., Jennewein M.F., Battisti P., Reed S., Singh J., Mohamath R., Bakken J., Beaver S. A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability. npj Vaccin. 2022;7:136. doi: 10.1038/s41541-022-00549-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  168. Vollrath I., Friess W., Freitag A., Hawe A., Winter G. Comparison of ice fog methods and monitoring of controlled nucleation success after freeze-drying. Int. J. Pharm. 2019;558:18–28. doi: 10.1016/j.ijpharm.2018.12.056. [DOI] [PubMed] [Google Scholar]
  169. Wan J., Wang Z., Wang L., Wu L., Zhang C., Zhou M., Fu Z.F., Zhao L. Circular RNA vaccines with long-term lymph node-targeting delivery stability after lyophilization induce potent and persistent immune responses. MBio. 2024;15 doi: 10.1128/mbio.01775-23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  170. Wang W. Lyophilization and development of solid protein pharmaceuticals. Int. J. Pharm. 2000;203:1–60. doi: 10.1016/s0378-5173(00)00423-3. [DOI] [PubMed] [Google Scholar]
  171. Wang W., Singh S., Zeng D.L., King K., Nema S. Antibody structure, instability, and formulation. J. Pharm. Sci. 2007;96:1–26. doi: 10.1002/jps.20727. [DOI] [PubMed] [Google Scholar]
  172. Wang J., Searles J.A., Torres E., Tchessalov S.A., Young A.L. Impact of annealing and controlled ice nucleation on properties of a lyophilized 50 mg/ml MAB formulation. J. Pharm. Sci. 2022;111:2639–2644. doi: 10.1016/j.xphs.2022.05.016. [DOI] [PubMed] [Google Scholar]
  173. Wang Z., Li L., Ren G., Duan X., Guo J., Liu W., Ang Y., Zhu L., Ren X. A comprehensive review on stability of therapeutic proteins treated by freeze-drying: induced stresses and stabilization mechanisms involved in processing. Dry. Technol. 2022;40:3373–3388. [Google Scholar]
  174. Wang T., Sung T.-C., Yu T., Lin H.-Y., Chen Y.-H., Zhu Z.-W., Gong J., Pan J., Higuchi A. Next-generation materials for RNA–lipid nanoparticles: lyophilization and targeted transfection. J. Mater. Chem. B. 2023;11:5083–5093. doi: 10.1039/d3tb00308f. [DOI] [PubMed] [Google Scholar]
  175. Wang T., Yu T., Li W., Liu Q., Sung T.-C., Higuchi A. Design and lyophilization of mRNA-encapsulating lipid nanoparticles. Int. J. Pharm. 2024;662 doi: 10.1016/j.ijpharm.2024.124514. [DOI] [PubMed] [Google Scholar]
  176. Ward K.R., Matejtschuk P. In: Cryopreservation and Freeze-drying Protocols. Wolkers W.F., Oldenhof H., editors. Springer US; New York, NY: 2021. The principles of freeze-drying and application of analytical technologies; pp. 99–127. [DOI] [PubMed] [Google Scholar]
  177. Wen L., Zhang Y., Sun C., Wang S.S., Gong Y., Jia C., Luo J. Fundamental properties and principal areas of focus in antibody–drug conjugates formulation development. Antib. Ther. 2025;8:99–110. doi: 10.1093/abt/tbaf005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  178. Wijewickreme A.N., Kitts D.D. Influence of reaction conditions on the oxidative behavior of model Maillard reaction products. J. Agric. Food Chem. 1997;45:4571–4576. [Google Scholar]
  179. Zhang Y., Binner J., Rielly C., Vaidhyanathan B. Comparison of spray freeze dried nanozirconia granules using ultrasonication and twin-fluid atomisation. J. Eur. Ceram. Soc. 2014;34:1001–1008. [Google Scholar]
  180. Zhang C., Berg A., Joe C.C.D., Dalby P.A., Douglas A.D. Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration. npj Vaccin. 2023;8:85. doi: 10.1038/s41541-023-00674-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  181. Zhang J., Guo M., Luo M., Cai T. Advances in the development of amorphous solid dispersions: the role of polymeric carriers. Asian J. Pharm. Sci. 2023;18 doi: 10.1016/j.ajps.2023.100834. [DOI] [PMC free article] [PubMed] [Google Scholar]
  182. Zhao P., Hou X., Yan J., Du S., Xue Y., Li W., Xiang G., Dong Y. Long-term storage of lipid-like nanoparticles for mRNA delivery. Bioact. Mater. 2020;5:358–363. doi: 10.1016/j.bioactmat.2020.03.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  183. Zhi L., Chen Y., Lai K.-Y., Wert J., Li S., Wang X., Tang X., Shameem M., Liu D. Lyophilization as an effective tool to develop AAV8 gene therapy products for refrigerated storage. Int. J. Pharm. 2023;648 doi: 10.1016/j.ijpharm.2023.123564. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

No data was used for the research described in the article.


Articles from International Journal of Pharmaceutics: X are provided here courtesy of Elsevier

RESOURCES